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ABSTRACT
The first project focused on the preparation, characterization, and application of dual emission
quantum dot encoded mesoporous silica microparticles.

The quantum dots were added in

precisely controlled ratios and were stably encapsulated within the pores of the silica. Several
experiments were performed to test the superior stability of the quantum dot-silica composites
over dye-loaded silica particles. The composite particles exhibited very high fluorescence, were
functionalized with antibodies, and were used as signal transducers for the detection of a protein
expressed by breast cancer cells.

The second project focused in more detail on the detection capabilities of the quantum dot-silica
composites. Three different types of quantum dot-silica composites were prepared. Each type
was loaded with a separate type of quantum dot with distinct emission wavelengths and was
functionalized with separate antibodies for detection of three different breast cancer biomarkers.
These three composite sensors were used together for the simultaneous detection of each of the
breast cancer markers. The initial strategy utilized the direct detection method in which the
antigen is nonspecifically adsorbed to a glass plate. An improved second strategy was more
sensitive and used a capture antibody which was covalently bound to a glass plate to immobilize
the antigen.

The third project focused on the preparation and application of magnetic, fluorescent human
serum albumin nanoparticle composites.

A fluorescent drug analogue and iron oxide

nanoparticles were encapsulated into 100 nm human serum albumin nanoparticles.

The

advantage of these composite particles is that they could be used as a theranostic tool which

x

could target, detect, and treat diseased tissue in a single application.

Release of the drug

analogue from the nanocomposites was achieved by addition of proteolytic enzymes that are
expressed or overexpressed in cancer cells.

The temporal release of the fluorescent drug

analogue was measured as a function of enzyme concentration. The amount of drug released
was directly proportional to enzyme concentration.

Keywords: Nanoparticles; quantum dots; fluorescence; multiplexing; enzymatic degradation;
breast cancer detection

xi

Chapter 1

Introduction
1.1 Objectives and Aims

The main objective of the research projects was to develop luminescent quantum dot
composite particles for the detection of breast cancer markers and to measure the release of a
fluorescent drug analogue from biodegradable human serum albumin (HSA) nanoparticles.
Quantum dots offer several advantages over conventional fluorophores.

One of the major

advantages is the broad absorption spectra of quantum dots. This enables quantum dots with
different emission wavelengths to be excited by a single wavelength. This is important because
it allows for multiplexing. The specific aims of study were i) to prepare and characterize highly
stable silica-quantum dot composites, ii) to develop quantum dot-mesoporous silica
microcomposites for biomarker analysis, and iii) to prepare and apply BODIPY-Vinblastine
encoded magnetic HSA particles for the detection of a breast cancer marker and to measure the
release as a function of enzyme concentration.

1.2 Significance

The ability for a sensitive assay to rapidly and reliably detect levels of breast cancer markers
is in high demand in cancer research. It is important for early diagnosis and improved prognosis.
The current methods to detect levels of breast cancer markers use fluorophores to measure gene
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expression and protein localization.

Fluorophores have several chemical and photophysical

limitations, such as broad emission spectra, poor photostability, low fluorescence quantum yields,
and the inability to perform multicolor detection. However, luminescent quantum dots have unique
electronic and optical properties that make them very desirable in biological research. A major field

of study in cancer research is the simultaneous detection of cancer markers. The ability to detect
cancer markers early can reduce cost and improve prognosis. One research project focused on
the development of a fluoroimmunoassay that can simultaneously detect three very common
breast cancer markers. Another research project focused on measuring the release of drug
analogue from magnetic, fluorescent HSA composites. The composite particles can be used in
cancer research for both magnetic targeting and treatment such as magnetic hyperthermia.

1.3 Fluorescence Principle

1.3.1

Jablonski Diagram

Fluorescence is the emission of one or more photons by an atom or molecule activated by
the absorption of a photon of electromagnetic radiation. This phenomenon can be illustrated by
the Jablonski Diagram (Figure 1.1).
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Figure 1.1 The Jablonski (energy-level) diagram for a photoluminescent molecule. S0, S1, and S2 are the singlet
gound state and the first and second excited electronic states, respectively. T1 is the first electronic triplet state.

Fluorescence occurs when the electron of a fluorophore is excited by the absorption of
electromagnetic radiation to produce a higher energy singlet state (S1 or S2) and returns to the
ground (S0) state by emission of a photon. Emission involves the transition from the lowest
vibrational level of the first excited electronic singlet state. The lifetime of fluorescence is about
10-7 to 10-9 s. The absorption of a photon of radiation occurs in about 10-14 to10-15 s. After
absorption, the electron is excited to any of the higher energy vibrational levels (depicted by the
blue and green arrows in Figure 1.1). The four significant nonradiative deactivation processes are
internal conversion, vibrational relaxation, external conversion, and intersystem crossing. Internal

conversion takes place whenever the electron relaxes to the lowest vibrational level of S1 or when
a molecule moves to a lower energy electronic state without emission of radiation. The excited
electron returns to its ground state via vibrational relaxation (shown by the dotted arrows in
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Figure 1.1) and light is emitted. Vibrational relaxation occurs in about 10-12 s. The vibrational
energy is immediately lost because of collisions between the molecules of the excited
fluorophore and the molecules of the solvent.1, 2 External conversion is the deactivation of an
electronic excited state caused by interaction and energy transfer between the excited
fluorophore and the solvents or other solutes. In fluorescence, the emission spectrum is the
mirror image of S0? S1 of the absorbance spectrum because the same transitions are involved in
both absorption and emission, and the vibrational levels of S0 and S1are similar. For a given
molecule, fluorescence occurs at longer wavelengths than absorbance because the energy of
emission is less than that of absorption. This energy difference occurs because upon excitation
into higher electronic and vibrational energy levels, the energy is rapidly dissipated as a result of
vibrational relaxation and internal conversion. Therefore, emission usually occurs from the
lowest vibrational level of S1.
In fluorescence, the spin of the excited electron in the singlet state is paired with the
ground state electron. When the spin of an electron in S1 are reversed, there is a transition from
S1 to T1. This is called intersystem crossing. Emission from T1 is called phosphorescence.
Because transition from T1 to S0 is forbidden, the phosphorescence lifetime is much longer than
fluorescence (10-4 s to 10 s vs 10-7 to10-9 s). Both fluorescence and phosphorescence are the
same in that excitation is caused by absorption of photons. Fluorescence is different from
phosphorescence because the electronic energy transitions in fluorescence do not involve a
change in electron spin.
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1.3.2

Factors that Affect Fluorescence

The chemical environment and structure of a substance determine whether it will
fluoresce and have a high or low quantum yield. The quantum yield is the ratio of the number of
photons emitted to the total number of photons absorbed.2 Highly fluorescent molecules have
quantum yields that approach unity; whereas, non-fluorescent molecules have quantum yields
that approach zero. Fluorescence mainly occurs in compounds that have ? ? ? * transitions
because they have much higher molar absorptivities that result in shorter fluorescence lifetimes
and because the deactivation processes that compete with fluorescence are minimized.
Compounds that contain aromatic functional groups with low energy ? ? ? * transition
levels, highly conjugated double bond structures, or aliphatic and alicyclic carbonyl structures
exhibit fluorescence. Substitution of the carbonyl or carboxylic acid groups on an aromatic ring
prevents fluorescence. Solvents or solutes that contain heavy atoms and halogen substitution on
an aromatic ring cause the heavy atom effect which increases the probability of intersystem
crossing and decreases the fluorescence intensity as the molecular weight of the halogen
increases. Other factors that affect the quantum yield of a molecule include temperature, pH,
paramagnetism, and concentration.

1.4 Structural Properties of Quantum Dots

Quantum dots (QDs) are small, spherical, fluorescent semiconductor nanocrystals composed
of periodic groups of II–VI (CdS, CdSe, CdTe, ZnO, ZnSe), III–V (InP, InAs, GaN, GaP, GaAs), or
IV-VI (PbS, PbSe, PbTe) materials.

These nanocrystals range from 2 to 10 nanometers in
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diameter and can contain hundreds to thousands of atoms. QDs approach the size of the exciton
Bohr radius and differ from bulk semiconductors in that they are characterized by discrete
atomic-like states with bandgap energies that are determined by the QD radius. This is called the
quantum-size effect which can be described by the spherical quantum box model:

Eg(QD) ˜ Eg0 + (h2? 2/2mehR2) (1)

where Eg(QD) is the QD energy gap, h is Planck’s constant, R is the radius of the quantum dot
and meh is the effective electron mass and effective electron hole mass. Quantum confinement
leads to increased stress on the exciton, which results in increased energy of the emitted photon. The
smaller the quantum dots, the less room for exciton separation, and more energy is required to form
the exciton.

Bulk semiconductors are characterized by continuous energy levels with a fixed bandgap
energy. Because of quantum confinement in QDs, a blue shift in the bandgap energy is produced
and causes a collapse of continuous energy levels of a bulk semiconductor into discrete atomiclike energy levels.3

1.4.1

Optical Properties of Quantum Dots

QDs undergo a process that is fundamentally the same as conventional fluorescence: in
semiconductors, the electron in the valence band can be excited by photon absorption and
promoted to the conduction band, creating a “hole” in the valence band. The excited electron
relaxes back to the valence band, fills the hole, and emits light. Because of the quantum
confinement effect, QDs have unique optical properties that offer several advantages over
6

conventional fluorophores. These advantages include a broad absorption spectrum, a narrow
emission spectrum, high photostability, high emission quantum yield, large molar extinction
coefficient, longer fluorescence lifetime, a large Stokes shift, and size dependent emission
wavelength tunability. The surface of QDs influences their photoluminescent properties. The
QD surface has defects called trap states that cause nonradiative electron energy transitions at the
surface. This results in a low quantum yield.4 The trap states are caused by vacancies, dangling
bonds, or adsorbates at the surface.

To reduce the effects the defects have on the

photoluminescence, QDs are coated with a shell that is a higher bandgap semiconductor. This
process is known as surface passivation. The shell is usually made of ZnS and greatly enhances
the quantum yield, chemical stability and photostability of the QDs.5-9

1.4.2

Synthesis of Quantum Dots

Size tuning of QDs is done by controlling the relative concentrations, rates of addition,
duration, temperature, and ligand molecules used in their synthesis.

QDs can be made as

colloidal solutions or grown on solid substrates.4 To make colloidal solutions, precursors of the
material are reacted in the presence of a stabilizing agent that will restrict the growth of the
particle and keep it within the quantum confinement limits. CdX (X= S, Se, Te) quantum dots
are the most widely used because of their emission in the UV-VIS-NIR region of the
electromagnetic spectrum. CdSe is the most popular choice of quantum dot material because it
has absorption energies that are tunable throughout the visible region, its precursors are
available, and its crystallization is simple. The most common procedure to synthesize CdSe
quantum dots is pyrolysis of organometallic precursors where dimethylcadmium Cd (CH3)2 is
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reacted with a selenium reagent in the presence of a phosphine oxide surfactant at high
temperature. This procedure was first reported in 1993 by Murray et al. and was later modified
by Peng et al. who replaced the extremely toxic cadmium precursor Cd(CH3)2 with CdO,
Cd(Ac)2 and CdCO3.10,

11

Other techniques to synthesize QDs include lipid bilayers, reverse

micelles, zeolites, porous glasses, vapor deposition reactions of precursors on solid substrates,
and hollow biological macromolecules.12-17
Over the years, QDs have been extensively used as fluorescent labels and probes. Some
biological applications involving QDs include biosensing18, celluar imaging19, in situ
hybridization20, and immunoassays.21
Despite being well studied and their high fluorescence quantum yields, CdSe/ZnS
quantum dots have little future in the biomedical field. CdSe/ZnS have many advantages over
typical fluorophores, but they are toxic and are environmentally restricted.22, 23 Quantum dots
made from III-V compounds, such as InP, are very desirable because they have very low toxicity
and are expected to have even greater quantum size effects.22, 24-27 InP/ZnS core/shell quantum
dots can be synthesized to emit into the near infrared region.

This is ideal for in vivo

applications. Although InP/ZnS quantum dots show a promising future, the use and information
on these quantum dots is very limited. Another limitation is that InP/ZnS quantum dots have
poor quantum yields. The best quantum yield achieved for InP/ZnS to date is 40% compared to
>75% for CdSe/ZnS quantum dots.23, 28 Other limitations of InP/ZnS quantum dots include poor
control of size distribution, poor size tunability, poor stability, and complicated synthesis.23
In a typical procedure to synthesize InP quantum dots, the reaction would take several
days and the mixture must be pumped under a vacuum with temperatures above 250 °C.29,

30

Other methods such as etching, developed by Weller and coworkers, involved the use of
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dangerous HF solutions to etch the InP nanocrystals.22, 26 In the past couple of years, Peng and
coworkers developed a simple one pot synthetic scheme to synthesize InP/ZnS quantum dots.
The synthesis was similar to that for CdSe quantum dots. The synthesis used relatively low
reaction temperatures below 200 °C and used In(AC)3 and myristic acid as precursors.23

1.4.3

Surface Modification of Quantum Dots

High quality quantum dots are typically synthesized and dispersed in organic solvents.
Three major limitations of having quantum dots stored in organic solvents are that the QDs are
insoluble in water, non-biocompatible and do not contain functional groups for bioconjugation.
In order for QDs to be used in aqueous biological systems, the hydrophobic trioctyl phosphine
oxide (TOPO) molecules that serve as capping ligands of luminescent quantum dots must be
replaced with bifunctional hydrophilic capping ligands or overcoated with an amphiphilic
protective layer in order to become water soluble and have functional groups that allow for
bioconjugation. The most common and well studied methods to prepare water soluble quantum
dots include ligand exchange, silica encapsulation, and coating with amphiphilic polymers and
phospholipids.

Ligand exchange involves the replacement of hydrophobic ligands with

bifunctional ligands in which one end binds to the inorganic QD surface and the other end
provides hydrophilicity. Thiol (-SH) groups are often used to bind to the ZnS surface via metal
affinity coordination. The TOPO capping ligands are often exchanged with thiol functionalized
compounds such as mercaptoacetic acid (MAA)31, 11-mercaptoundecanoic acid (MUA)32, 16mercaptohexadecanoic acid (MHDA)33, dihydrolipoic acid (DHLA)34, and dithiothreitol
(DTT).35 The bond between thiol and ZnS is not very strong and as a result quantum dots will
aggregate over time. This is one limitation of capping quantum dots with thiol containing
9

ligands.36 The displacement of TOPO molecules alters the chemical and physical state of the
surface atoms of quantum dot and reduces quantum efficiency.37 High silica encapsulation
involves the growth of a silica layer on the surface of quantum dots. Also, functional groups
such as –SH and –NH2 on the organosilane molecules are on the surface and enable
bioconjugation.38-41 The silica coated quantum dots are extremely stable because the silica layer
is highly cross-linked. However, the method is very laborious, difficult to reproduce, and the
silica layer may be hydrolyzed.42 Coating QDs with an amphiphilic polymer and phospholipids
is achieved by forming the layer on the QD surface via hydrophobic interactions with the
hydrophobic TOPO ligands. The hydrophilic exterior of the polymer enables the quantum dot to
be soluble in aqueous solutions.43 The TOPO ligands are not displaced from the surface;
therefore, the quantum dots retain their high quantum yield and are protected from the external
environment.

However, the final size of quantum dots is larger, which could limit many

biological applications such as FRET measurements and endocytosis.42
methods for developing water-soluble, biocompatible quantum dots.
advantages and limitations.

There are several

Each method has its

Synthesizing stable, high quality water-soluble quantum dots

remains in high demand in the area of quantum dot based nanobiotechnology.

1.4.4 Quantum Dots in Multiplexed Imuunoassays

One objective of this project was to encode mesoporous silica with quantum dots to
develop a fluoroimmunoassay that can simultaneously identify multiple breast cancer markers.
One of the great advantages of quantum dots is their narrow emission and broad absorption
spectra. This allows multicolored QDs that have different emission wavelengths to be excited at
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a single wavelength.

This technique is called multiplexing.

Multicolored QDs were

incorporated into mesoporous silica microparticles and labeled with antibodies specific for three
breast cancer antigens. These antibody labeled silica particles were used to detect different
concentrations of breast cancer antigens. Utilization of these particles for multiplexing was also
achieved.
An advantage of mesoporous silica is that the pores can be easily functionalized.44-46 Lin
and coworkers have done extensive research on synthesizing and functionalizing the pores using
a co-condensation method based on sodium hydroxide catalyzed reaction of tetraethoxysilane
(TEOS) with various organoalkoxysilanes in the presence of a low concentration of
cetyltrimethylammonium bromide (CTAB)surfactant.46 For example, fluorescein functionalized
Mobil Crystalline of Materials (MCM-41) type mesoporous silica nanoparticles (diameter: 150
nm, pore: 2.4 nm) containing 3-aminopropyl and N-folate-3-aminopropyl surface functional
groups were used to measure the endocytosis of the particles by human cervical cancer cells.47
Thiol functionalized MCM-41 type mesoporous silica nanoparticles (diameter: 150 nm, pore: 2.4
nm) with a poly(lactic-acid) coating were used to develop a fluorescence probe for the detection
of amino containing neurotransmitters.46 2-(propyldisulfanyl)ethylamine functionalized MCM41 type mesoporous silica nanoparticles (diameter: 200 nm, pore: 2.3 nm) were used to measure
the stimuli-responsive controlled release of neurotransmitters and drug molecules.48
Several research groups have reported the use of quantum dots in multiplexed
immunoassays. Wilson et al. used a layer by layer technique to create magnetic microspheres
encoded with photoluminescent quantum dots for the multiplexed detection of three different
explosives.49 Gao et al. described encapsulating luminescent quantum dots in ABC tri-block
copolymer to perform in vivo targeting and imaging of human prostate cancer cells growing in
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mice.19 Yezhelyev et al. used a hetero-bifunctional crosslinker to covalently attach multicolored
QDs to antibodies. These QD-antibody conjugates were used to perform in situ molecular
profiling of five different breast cancer biomarkers.20

1.5 Preparation of Human Serum Albumin Nanoparticles

Human serum albumin (HSA) is the most abundant blood plasma protein (molecular weight
65 kDa) that has a wide variety functions which will be discussed in more detail in chapter 5.
HSA has a blood concentration of 50 mg/mL and contains 585 amino acids. There are 35
cysteine residues which form 17 disulfide bridges and one free thiol. HSA can form dimers and
aggregates that can be used to prepare nanoparticles. The preparation of HSA nanoparticles and
microparticles was first proposed in 1972 by Scheffel and coworkers.50 It was based on an
emulsion method which was later modified by Gao and coworkers.51 An aqueous human serum
albumin solution is emulsified at room temperature by the addition of cotton seed oil. The
emulsion is then homogenized at high speed and added drop wise to a high volume of oil which
is pre-heated above 120°C. The water will be rapidly evaporated and albumin nanoparticles will
form. The major disadvantage of the emulsion method is the need for high volumes of organic
solvents which need to be properly removed for bioapplications.
An alternative desolvation method which eliminates the need for insoluble oils and high
temperatures was first suggested in 1978 by Marty and coworkers. 52 This method involves using
salts or alcohols to unfold the tertiary structure of albumin which will cause aggregates to form.
A crosslinking agent such as glutaraldehyde is then added to link the amino groups, and albumin
nanoparticles are formed.
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Langer and coworkers have done extensive research to optimize the preparation
conditions of HSA nanoparticles using the desolvation method. 53, 54 They found that the rate of
ethanol addition greatly influenced particle diameter and polydispersity. The optimal rate of
addition was between 1 and 2 ml/min to achieve monodiperse particles with an average diameter
around 150 nm. The pH of the HSA solution prior to the addition of ethanol also affected
particle size. The particle diameter and yield significantly decreased with pH > 7.

No

reproducible particle formation was achieved at pH < 7. The use of buffers in the desolvation
process interfered with glutaraldehyde crosslinking, formed large HSA aggregates, or
precipitation of the buffer salts. Therefore, NaCl is used for pH adjustment. The optimal salt
concentration to form monodisperse nanoparticles is 10 mM NaCl at pH 8.2.
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Chapter 2

Experimental
This chapter describes the general experimental information.
chemicals, supplies, and instrumentation for characterization.

This section includes

More detailed experimental

procedures will be discussed in subsequent chapters.

2.1 Chemicals and supplies

Cadmium oxide (CdO), lauric acid, trioctylphosphine (TOP), trioctylphosphine oxide
(TOPO), diethylzinc (Zn(Et)2), hexadecylamine (HDA), hexamethyldisllathiane ((TMS) S),
2

selenium powder, chloroform, methanol, bovine serum albumin (BSA), human serum albumin
(HSA) (3-mercaptopropyl)trimethoxysilane (MPTMS), 1-butanol, trizma base, and streptavidinmaleimide were all purchased from Sigma. Glass bottom well plates were purchased from
MatTek.

Three micron mesoporous silica particles with 32nm C18 modified pores were

purchased from Phenomenex. Superblock T20 PBS buffer and 20x PBS with Tween 20 was
purchased from Pierce. HER2/neu protein was purchased from Invitrogen. Human HER2/neu
affinity purified biotinylated polyclonal antibody was purchased from R&D Systems. Estrogen
Receptor a (ER a) and Progesterone receptor (PR) protein were purchased from Abcam.
BODIPY-vinblastine was purchased from Invitrogen. Ten nanometer diameter PEG coated iron
oxide particles were purchased from Ocean Nanotech. All aqueous solutions were prepared with
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18 MO deionized water produced by a water purification system (Barnstead Thermolyne
Nanopure). All chemicals were used as received without further purification.

2.2 Characterization

2.2.1 Fluorescence emission spectra

Fluorescence emission measurements were performed using a SpectraMax M2
microplate reader (Molecular Devices, Inc.) equipped with a Xenon flash lamp source and a
photomultiplier (R-3896) detector. Microplate readers are multi-detection systems with a double
monochromator and dual-mode cuvette ports. The system is equipped with a spectrophotometer
for absorbance measurements and a spectrofluorometer for fluorescence measurements.
The microplate reader has an excitation monochromator and an emission monochromator
for separating different wavelengths. In this device, the output of a xenon flash lamp light source
is directed to a concave holographic grating for tuning the different excitation wavelengths.
Holographic gratings are a type of diffraction grating that exhibit less scattered light than other
grating types.1 They are composed of a polished substrate coated with a photoresist to reduce
astigmatism at multiple angles. The excitation light travels through 1 mm fiber optic bundles to
cuvette ports and microplates. In the cuvette mode, the incident light is reflected by an elliptical
mirror and directed to the cuvette. When in fluorescence mode, the fluorescence emission of
fluorescent probes is focused on an elliptical mirror and directed to a concave holographic
grating. The light then reaches the photomultiplier tube. For microplate mode, the light passes
through the second fiber optic to a focusing elliptical mirror. The light beam penetrates the top
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of the microplates and passes through the sample. The fluorescence light is collected and
directed to the second wavelength isolation module and then to the photomultiplier tube.

2.2.2 Photomultiplier tubes

Photomultiplier tubes (PMTs) are very sensitive to UV/Vis radiation. Advantages of
using PMTs as detectors include their fast response times and their ability to amplify low
intensity light signals. Disadvantages include dark current interferences and damage if the PMT
is exposed to high power radiation.2 The dark current interferences can be minimized by cooling
the system. The photocathode generates electrons upon being struck by light. The dynodes are
held at a more positive potential than the cathode which causes the electrons to be accelerated
toward the dynodes. Each dynode is at a more positive potential than the previous dynode. Each
photoelectron produces several additional electrons upon striking the dynode. This causes the
current from each incident photon to be multiplied by 106. The photocathode is covered by a
quartz envelope.

2.2.3 Digital fluorescence imaging microscopy

Fluorescence images were taken using a digital fluorescence imaging microscopy system
that contained an Olympus IX71 inverted fluorescence microscope equipped with a 100 W
mercury lamp as a light source and a high performance color charge coupled device camera
(CCD) (Olympus DP 70). The fluorescence images were obtained through a 20x microscope
objective using a filter cube containing a 425 ±20 nm band-pass excitation filter, a 465 nm
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dichroic mirror, and a 475nm long pass emission filter. The exposure time was 20 ms and
numerical aperture was 0.5. Numerical aperture is the range of angles over which the system can
emit light. The software Image-pro Plus and DP Controller were used for image analysis. The
microscope contains a trinocular observation head that is coupled to a CCD camera system, and
has two illumination sources, one for transmitted light and the other for episcopic observations.4
Fluorescence microscopy demonstrates the properties of fluorescence emission of molecules
upon specific excitation and gives information about their spatial distribution with direct
application in biological experiments. The output of the lamp passes through collecting optics to
a filter cube that contains a set of excitation and emission filters and a dichroic mirror. The
fluorescence produced after excitation of the sample is collected by the objective and directed
through different paths to the CCD and eyepiece.
Microscope objectives are designed to focus excitation light on a sample and to collect
emission light from the sample. When excitation and emission light travel through the same
objective it is called epifluorescence microscopy.

Epifluorescence separates excitation and

emission light. The spatial resolution, R, of a microscope is defined as the minimum separation
distance between two distinguishable points in a field:

R = 1.22?/2(NA) (1)
NA= n sina

(2)

where NA is the numerical aperture of the objective, n is the refractive index of the medium
surrounding the lens, a is the angular aperture which is the angle between the microscope optical
axis and the oblique light rays captured by the objective, and ? is the wavelength.4 How bright
the image will be depends on the light gathering power of the objective. The light gathering
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power, F, of the objective is directly proportional to the square of the numerical aperture (NA)
and magnification (M):
F = 104 • (NA/M)2 (3)

Excitation and emission filters are placed in front and underneath the dichroic mirror.
The excitation filters are located in front of the dichroic mirror and select the desired excitation
wavelength. Reflection losses take place at the boundary of the excitation filter due to changes
in the refractive index. Emission filters placed underneath the dichroic mirror select the desired
emission wavelength and eliminate residual excitation light. A dichroic mirror is a color filter
which separates the excitation and emission paths. The surface of the mirror is coated with a thin
layer of metal.

The thickness and type of coating control the percent of reflectivity and

transmission of incident light. The values below the transition wavelength are reflected into the
objective, while the ones above the value are transmitted. The excitation light reflected by
dichroic mirrors is directed through the objective to excite the fluorescent probes.

2.2.4 Charge-coupled device

A CCD camera has a great sensitivity to low light levels and contains a thin silicon wafer
divided into an array of several light-sensitive regions that capture and store image information
in the form of localized electrical charge that depends on the incident light intensity. The
electronic signal that corresponds with each pixel of the detector has an ouput as an intensity
value for the corresponding image location. After the values are digitized, the image can be
reconstructed and displayed on a computer monitor very rapidly.6

22

The pixel is made from p-type silicon and the electrons formed by the absorbed radiation collect
in the well below the electrode.

The holes move away from the n-type layer toward the

substrate.2 The accumulated charge is measured by a three phase clock circuit that shifts the
charge. The charges are transferred to a preamplifier and finally read out.
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Chapter 3

Dual Emission quantum dot-labeled silica particles for Bioanalytical
Assays

3.1 Abstract

Chapter 3 discusses the preparation and characterization of mesoporous silica particles
encoded with highly fluorescent CdSe/ZnS quantum dots for the detection of breast cancer
markers. A rapid and simple method for encoding mesoporous silica particles with quantum dots
(SiQDs) for the simultaneous detection of multiple analytes in complex mixtures is described.
The assay was based on the use of quantum dot-containing mesoporous silica particles as signal
transducers. To prepare the composite particles CdSe/ZnS quantum dots were incorporated into
meosoporous silica particles of 3 µm diameter and 35 nm pore size. The incorporation of the
quantum dots into the mesoporous silica spheres was completed in 30 minutes. By using this
simple and efficient incorporation method, it was possible to stably encapsulate quantum dots of
different diameter (and emission color) in the silica particles. It was also possible to incorporate
mixtures of quantum dots of different emission color and precisely control the ratio between
quantum dots of different emission colors in the silica particles. This could facilitate the use of
the quantum dot-silica composites in luminescence assays of multiple analytes in which
composite silica particles of different emission colors are used to identify and quantify specific
analytes in a complex mixture.

To demonstrate the capabilities of the quantum dot-silica
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composite particles, the composite particles were applied for the analysis of multiple breast
cancer markers.

3.2 Introduction

Fluorescent microparticles have been widely used in bioanalytical assays as fluorescent
tags primarily due to their high fluorescence intensity and ability to label biomolecules with a
relatively simple coupling chemistry1-8. Silica and polystyrene fluorescent particles are typical
examples of fluorescent particle technology. They are commonly prepared by incorporating
organic dye molecules into the particles during or following their synthesis. Nie and coworkers
reported the synthesis and application of semiconductor quantum dots (QD) into polystyrene
paticles9,10.

Multiple DNA targets were detected by labeling multicolored QD encoded

polystyrene with probe DNA strands. QD are particularly attractive because of their unique
optical properties that offer several advantages over conventional fluorophores. These include
broad absorption spectra, narrow emission peaks, high photostability, high emission quantum
yields, large molar extinction coefficients, relatively long fluorescence lifetimes, large Stokes
shifts, and size dependent emission wavelength tunability11-17. These advantages make quantum
dots well suited for multiplex analysis. High quality quantum dots are typically synthesized and
dispersed in organic solvents. Three major limitations of having quantum dots stored in organic
solvents are that the QDs are insoluble in water, are not biocompatible and do not contain
functional groups for bioconjugation. In order for QDs to be used in aqueous biological systems,
the hydrophobic TOPO molecules that serve as capping ligands of luminescent quantum dots
must be replaced with bifunctional hydrophilic capping ligands or overcoated with an
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amphiphilic protective layer in order to become water soluble and have functional groups that
allow for bioconjugation. Polystyrene and silica encapsulation are two of the most common and
well studied methods to prepare water soluble quantum dots. The polystyrene microparticles
were prepared using microemulsion and the luminescent QD were loaded after swelling the
polystyrene with an organic solvent. Nie and coworkers demonstrated that it is possible to
control the ratio between QD of different emission color in the polystyrene particles with high
precision9,10.

In our laboratory we have carried out similar experiments and encountered

difficulties in loading large amounts of QD into polystyrene particles, which often resulted in
their structural deformation. We therefore directed our attention to the more rigid silica particles
and focused on mesoporous silica particles since we already demonstrated the incorporation of
ruthenium complexes into silica particles using a one-step Stöber synthesis method18-20. Unlike
the microemulsion method, the Stöber technique does not involve the use of potentially toxic
organic solvents and surfactants21-23. Conjugation of biomolecules to the particles is easier
because there is no need to repetitively and thoroughly wash surfactant molecules from the
particles.
In addition, it has already been shown by Lin and coworkers that QD could be
successfully incorporated into mesoporous silica particles without altering their structural
morphology24.

Lin and coworkers have also done extensive research on synthesizing and

functionalizing the mesopores using a co-condensation method based on sodium hydroxide
catalyzed reaction of tetraethoxysilane (TEOS) with various organoalkoxysilanes in the presence
of a low concentration of cetyltrimethylammonium bromide (CTAB) surfactant25. For example,
fluorescein functionalized Mobil Crystalline Materials (MCM-41) type mesoporous silica
nanoparticles (diameter: 150 nm, pore: 2.4 nm) containing 3-aminopropyl and N-folate 3-
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aminopropyl surface functional groups were used to measure the endocytosis of the particles by
human cervical cancer cells26.

Thiol functionalized MCM-41 type mesoporous silica

nanoparticles (diameter: 150 nm, pore: 2.4 nm) with a poly(lactic-acid) coating were used to
develop a fluorescence probe for the detection of amino containing neurotransmitters25. 2(propyldisulfanyl)ethylamine functionalized MCM-41 type mesoporous silica nanoparticles
(diameter: 200 nm, pore: 2.3 nm) were used to measure the stimuli-responsive controlled release
of neurotransmitters and drug molecules27.
In this paper, we describe the preparation and characterization of QD-incorporating
mesoporous silica particles and demonstrate their application for the analysis of breast cancer
markers in solution.

3.3 Experimental

3.3.1 Synthesis of TOPO coated quantum dots

TOPO coated CdSe/ZnS quantum dots were prepared by a method developed by Peng
with slight modifications15, 16. Briefly, 12.7 mg cadmium oxide (CdO) and 160 mg lauric acid
were mixed in a 3-neck flask under nitrogen and heated to >200 °C until the CdO was dissolved
in the lauric acid. A clear, colorless solution was formed. Then, 1.9 g of trioctylphosphine oxide
(TOPO) and 1.9 g hexadecylamine (HDA) were added to the solution under stirring and the
temperature was increased to 280°C for 10 min. Next, 80 mg selenium powder was dissolved in
2mL of trioctylphosphine (TOP) and was rapidly injected into the solution under vigorous
stirring. The mixture was cooled to ~200 °C and kept at this temperature for 3 minutes. When
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the quantum dots reached the desired color, a ZnS shell was added as follows: a 2 mL of TOP
solution containing 250 µL hexamethyldisilathiane ((TMS) S) were mixed with 1 mL diethylzinc
2

(Zn(Et) ) was premixed well under nitrogen and then slowly injected into the solution. The
2

reaction mixture was kept at 180 °C for one hour. The solution was then cooled to room
temperature and the resulting TOPO coated CdSe/ZnS quantum dots were washed three times
with methanol and re-dispersed in chloroform. Scheme 3.1 shows the synthesis of CdSe/ZnS
quantum dots.

Scheme 3.1. Schematic representation of the sythesis of CdSe/ZnS core/shell quantum dots

3.3.2 Preparation of mesoporous and thiol-modified fluorescent silica microparticles

Mesoporous fluorescent silica microparticles were prepared by dispersing 2mg of
mesoporous silica particles, averaging 3 µm in diameter with 32 nm C18 modified pores in 1 mL
butanol. Two hundred microliters of 1 µM green emitting TOPO capped CdSe/ZnS QD (? em
=545 nm) or red emitting CdSe/ZnS QD (? em = 655 nm) or a mixture of green and red emitting
QD were added to the solution. The mixture was incubated for 30 minutes and then washed
three times with ethanol. Thiol-modified fluorescent mesoporous silica microparticles were
prepared according to a previously described method18,
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. Briefly, 2mg of fluorescent QD

loaded silica particles were dispersed in 10 ml of butanol. Five hundred microliters of 3mercaptopropyltrimethoxysilane (MPTMS) were added to the solution.

The mixture was

incubated for 30 minutes and washed three times with ethanol. The particles were then redispersed in 4mL of phosphate buffer (PB) containing 0.1% BSA at pH 7.4.

3.3.3 Preparation of streptavidin-modified fluorescent mesoporous silica beads –

Streptavidin-modified fluorescent mesoporous silica beads were prepared according to a
previously described method19. Briefly, 1 mL of thiol-modified fluorescent mesoporous silica
stock solution was added to 2mg streptavidin-maleimide in 5mL PB containing 0.1% BSA at pH
7.4. The mixture was incubated under gentle stirring for three hours at room temperature. The
streptavidin-labeled beads were separated by centrifugation (5500 rpm, 10min) and washed three
times with PB. The streptavidin-labeled fluorescent mesoporous silica beads were re-dispersed
in 4 mL PB and used immediately for biotin-avidin assays.

3.3.4 Preparation of anti HER2/neu labeled fluorescent mesoporous silica beads –

Anti-HER2/neu labeled fluorescent mesoporous silica particles were prepared by mixing
1mL streptavidin modified silica particles with 50 µg of biotinylated anti-HER2/neu in 1 mL
PBS. The anti-HER2/neu labeled particles were incubated at room temperature for two hours.
The anti-HER2/neu labeled particles were separated by centrifugation (5500 rpm, 10min) and
washed three times with PBS at pH 7.4. The particles were then re-dispersed in 4 mL PBS at pH
7.4 and immediately used for binding assays.
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3.3.5 Preparation of HER2/neu coated 96-well plate –

A glass bottom 96-well plate was coated with HER2/neu protein through nonspecific
adsorption by adding 100 µL HER 2 protein at concentrations of 10 µg/mL, 5 µg/mL, 2 µg/mL,
0.1 µg/mL, 85 ng/mL and 65 ng/mL. Each concentration of protein was added to three wells.
The plate was incubated for 20 hrs at 4°C. Unoccupied sites were blocked by adding 300 µL of
Superblock T20 PBS buffer. One hundred microliters of anti HER2/neu labeled silica particles
were added and incubated for 2 hours. The plate was washed with PBS containing 0.05%
Tween-20 and dried under a stream of nitrogen.

3.3.6 Characterization of particles by TEM and SEM –

SEM images were taken on a Hitachi S-4800 Field Emission SEM at 3kV without coating.
SEM images were taken at a magnification of 20, 000 x. TEM images were taken on a JEOL
2011 TEM at 200kV. TEM images were taken at a magnification of 6, 000 x.

3.4 Results and Discussion

3.4.1 Fluorescence properties of fluorescent mesoporous silica beads –
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Three micron fluorescent mesoporous silica microparticles were prepared as described in the
experimental section. Figure 3.1 shows fluorescence microscopy images and corresponding
spectra of mesoporous silica particles that contain only green emitting QD (a), only red emitting
QD (b) and mixtures of QD with 1:5 (c), 1:1 (d), and 3:1 (e) ratios. It can be clearly seen that the
emission properties of the silica microspheres could be controlled and that the green and red
emission peaks are baseline separated. The particles in figure 3.1 c have a 1:5 loading of green
to red QD.

The particles appear reddish yellow.

The yellowish color is a result of the

combination of both green and red emitting QD. The particles in c appear to be more red than
green because there are five times more red QD than green (see spectrum). The particles in
figure 3.1 d have a 1:1 loading of green to red QD in the silica. There is a more homogenous
yellow color than in c because of the even loading of green and red QD. The particles in figure
3.1 e appear green because there are three times more green QD than red. The emission
properties of the fluorescent mesoporous silica beads were similar to the emission properties of
green and red emitting QDs (data not shown).
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Figure 3.1 - Digital fluorescence microscope images and fluorescence spectra (? ex = 400 nm) of (a) 3 µm
mesoporous silica particles that contain 545 nm green emitting CdSe/ZnS QD, (b) 655 nm red emitting CdSe/ZnS
QD, (c) and green and red emitting QD mixtures with 1:2, (d) 1:1,and (e) 3:1 ratios. A typical exposure time was
150 msec.

3.4.2 Characterization of fluorescent mesoporous silica beads

Figure 3.2 shows microtome TEM and SEM images along with EDS spectra of mesoporous
silica particles with and without QD. The microtome TEM samples were cut to have a 70 nm
thickness. The incorporation of QD did not affect the morphology of the silica particles. EDS
shows both Cd and S peaks indicating the presence of QD in the pores; whereas, there are no Cd
or S peaks for mesoporous silica without QD.
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Figure 3.2 – Characterization of mesoporous silica (a) SEM image of mesoporous silica particles without quantum
dots, (b) microtomeTEM image of mesoporous silica particles without quantum dots, (c) EDS spectrum of
mesoporous silica particles without quantum dots, (d) SEM image of mesoporous silica particles with quantum dots,
(e) microtomeTEM image of mesoporous silica particles with quantum dots, and (f) EDS spectrum of mesoporous
silica particles with quantum dots

3.4.3 Luminescence properties of fluorescent mesoporous silica beads

Figure 3.3 compares the photostability of mesoporous silica loaded with 1:1 545 nm and 655
nm emitting CdSe/ZnS QD, 545 nm and 655 nm emitting QD, and mesoporous silica loaded
with

fluorescein

DHPE

(1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine),

and

rhodamine DHPE. All solutions were illuminated continuously for 2 hours using a 100W
mercury lamp. It can be clearly seen that the QD-containing silica microparticles exhibit higher
photostability than free QD and significantly higher photostability than fluorescein and
rhodamine DHPE. The fluorescence intensity of 545 nm or 655 nm QD-containing silica
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microparticles decreased by 45% and 30% respectively over 2 hours of illumination compared to
their original intensity. The fluorescence intensity of green and red-emitting QD solutions
decreased by 60% and 55% compared to their original intensities. The fluorescence intensity of
solutions of rhodamine and fluorescein-containing mesoporous silica particles decreased by 80%
and 85% compared to their original intensity under the same illumination conditions.
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It is interesting to note that the emission intensity of QD and QD-containing mesoporous silica
microparticles did decrease during illumination although to a significantly lesser extent than the
fluorescence decrease for molecular organic fluorphores. While the fluorescence of organic
fluorophores decreased due to photobleaching, the decrease in the emission of the QD is
attributed to surface photo-oxidation or photo-corrosion28. It appears that encapsulation of QD in
mesoporous silica microparticles decreases their rate of photo-oxidation, which is a significant
advantage over the use of free QD or organic fluorophores.

3.4.4 Leakage of quantum dots from mesoporous silica

Leakage of QD from the mesoporous silica microparticles is a significant concern since the
QD were loaded into the mesoporous silica microparticles and could conceivably leak out of the
particles to the solution. Leakage of QD, fluorescein DHPE, and rhodamine DHPE from the
silica particles was monitored for 10 days by adding the loaded mesoporous silica microparticles
to butanol and measuring the fluorescence intensity of supernatant samples daily. Figure 3.4
shows that supernatants of solutions of green and red emitting QD-containing mesoporous silica
microparticles did not show a measurable fluorescence signal during 10 days of observation.

36

6000

Fluorescence Intensity

5000
4000
3000
2000
1000
0
1

2

3

4

5

6

7

8

9

10

Days

This minimal leakage of QD from the mesoporous silica microparticles is attributed to strong
hydrophobic interactions between the hydrocarbon molecules of the pore walls and the TOPO
molecules on the quantum dot surface. In contrast, the fluorescence intensity of the supernatant
collected from solutions of fluorescein DHPE and rhodamine DHPE-containing mesoporous
silica microparticles had an increase in intensity during the first day of observation.

The fast

leakage during the first day may be attributed to the release of fluorescein-DHPE and rhodamine37

DHPE that were loosely attached to the particle surface. This was followed by a slower leakage
component of fluorescein-DHPE and rhodamine-DHPE molecules that were incorporated into
the pores but leaked out over time to the solution due to their amphiphilic nature.

C-18

CdSe core

ZnS shell

Scheme 3.2. Schematic representation of the interaction between the C-18 hydrocarbon chain of the pore wall and
the TOPO molecules on the quantum dot surface.

3.4.5 Effect of temperature on the fluorescence intensity of the silica-quantum dot
composites

Figure 3.5 shows the effects of temperature on the fluorescence intensity of the particles.
The particles have the highest fluorescence intensity at room temperature and decreases as the
temperature is increased. The greatest decrease in fluorescence intensity was at 100 °C. This is
expected because of the deactivation process caused by the increased frequency of collisions at
higher temperatures.
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Figure3.5 - Effect of temperature on the stability of the silica-quantum dot composites.
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85 °C, and
100 °C.
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3.4.6 Stability of quantum dots in mesoporous silica microparticles
In order to protect the quantum dots in the silica pores, MPTMS was added which
polymerizes upon addition of water.

Fluorescence measurements were taken of SiQDs with

MPTMS and without MPTMS for ten days to monitor the effects of photo oxidation on the
fluorescent microparticles. Particles with MPTMS were more stable than those without. The
particles were loaded with a 1:1 ratio of 545 nm and 655 nm quantum dots. The composite
particles were separated into four categories: a) particles deoxygenated argon that were stored in
the dark, b) particles deoxygenated by argon that were stored in room light, c) particles with no
argon stored in the dark, and d) particles with no argon stored in room light. Figure 3.6

39

demonstrates a negligible change in the fluorescence intensities of mesoporous silica particles
containing argon that were stored in the dark.

For particles stored in the dark without argon,

there was a 4% decrease in fluorescence intensity for SiQDs with MPTMS and a 38% decrease
for particles without MPTMS. There was a 13% decrease in fluorescence intensity for SiQDs
with MPTMS stored under argon in room light and a 50% decrease in fluorescence intensity for
particles without MPTMS stored with argon stored in room light. The fluorescence intensity of
particles with no argon stored in room light with MPTMS had a decrease of 28% and 81% for
particles without MPTMS.
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Figure 3.6 - Stability of quantum dots in mesoporous silica with and without MPTMS. a) particles deoxygenated by
argon that were stored in the dark, b) particles deoxygenated by argon that were stored in room light, c) particles
with no argon stored in the dark, and d) particles with no argon stored in room light.
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3.4.7 Direct assay for the detection of the breast cancer marker HER2/neu –

The surface of the 3µm mesoporous silica particles were functionalized with thiol groups
because thiol is a reactive functional group that allows the covalent coupling of maleimide
modified biomolecules through the formation of thio-ether bonds. Maleimide-streptavidin was
attached to the surface of the fluorescent mesoporous silica particles in order to couple the biotin
labeled anti-HER2/neu through streptavidin-biotin interactions. A direct detection assay was
developed by nonspecifically adsorbing the HER2/neu protein to the surface of the glass well
plate, adding the anti-HER2 labeled fluorescent silica particles to the plate, washing, and
measuring the fluorescence intensities of the individual wells. The glass 96-well plate was
incubated with HER2/neu solutions ranging from 0 to 10 µg/mL in PBS buffer at pH 7.4 for 20
hours at 4°C. Unoccupied sites were blocked by adding 300 µL of Superblock T20 PBS buffer.
100 µL of anti HER2/neu labeled silica particles were added and incubated for 2 hours. The
plate was washed with PBS containing 0.05% Tween-20 and dried under a stream of nitrogen
before taking measurements. Figures 3.7 and 3.8 demonstrate the dependence of the binding of
the fluorescent anti-HER2/neu labeled particles (containing 1:1 of 545 nm and 655 nm QD) on
the concentration of HER2/neu. At concentrations of 0 and 65 ng/mL, there was no measureable
fluorescence signal. The fluorescence intensity continued to increase when the concentration of
HER2/neu increased from 85 ng/mL to 10 µg/mL. There were also no fluorescence signals for
unlabeled particles with 10 µg/mL HER2/neu nor with anti-HER2/neu labeled particles added to
50 µg/mL and 10 µg/mL of ERa and PR, respectively. No fluorescence signal for unlabeled
particles with HER2/neu indicates that there is no nonspecific binding which eliminates any false
positives. No fluorescence signal for anti-HER2/neu labeled particles in the presence of ERa
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and PR indicate that there is no cross reactivity between the anti-HER2/neu labeled particles and
ERa and PR. The cutoff level for HER2/neu in serum is 10 ng/mL. The limit of detection of
the direct assay was 85 ng/mL HER2/neu. The limit of detection values were determined by
measuring the fluorescence intensity as a function of HER2/neu concentration. This assay was
very reproducible yielding similar results for three separate experiments. A more detailed
explanation of the significance of the limit of detection values and comparison to other methods
will be given in Chapter 4.

Figure 3.7 - Dependence of the binding of the fluorescent anti-HER2/neu labeled particles on the concentration of
HER2/neu: Plot of fluorescence intensity versus HER2/neu concentration of 545 nm
and 655 nm SiQDs .
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Figure 3.8 - Digital fluorescence microscopy images of (a) Unlabeled anti-HER2 silica with 10 µg/mL HER2/neu,
(b) 0 µg/mL HER2/neu, (c) 50 µg/mL ER, (d) 10 µg/mL PR, (e) 65 ng/mL HER2/neu, (f) 85 ng/mL HER2/neu, (g)
0.1 µg/mL HER2/neu, (h) 2 µg/mL HER2/neu, (i) 5 µg/mL HER2/neu, and (j) 10 µg/mL HER2/neu.
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3.5 Summary and Conclusions

Some previously used methods for preparing fluorescent microparticles include the
incorporation of organic dyes and lanthanide oxides into beads by microemulsion and spray
pyrolysis, respectively. These methods can be both costly and laborious. Neither organic dyes
nor lanthanide oxides have high photostability, rapid and simple incorporation techniques, or the
ability to multiplex. It is impossible to precisely control the ratios of the fluorescent molecules
into the microparticles by the microemulsion and spray pyrolysis methods. The inability to
multiplex and the self-quenching effect of organic dyes are major disadvantages when
considering the use of these fluorescent microparticles in biological applications. The method
used in this study for preparing the fluorescent silica particles was rapid and simple. Unlike
polystyrene microparticles, the rigid silica particles were resistant to structural deformation.
545 nm, 655 nm, and several precisely controlled ratios of 545 nm and 655 nm quantum dot –
silica composites were prepared. QDs have several advantages over conventional fluorophores
including high photostability, high emission quantum yield, and size dependent emission
wavelength tunability. The use of quantum dots is ideal for multiplexing. The SiQDs showed
high photostability compared to dye labeled mesoporous silica particles and free quantum dots.
The quantum dot encapsulated particles showed very high stability to leakage compared to
particles loaded with fluorescein DHPE and rhodamine DHPE. The particles were very stable
when stored under argon in the dark and SiQDs containing MPTMS were much more stable than
unmodified particles. The composite particles were applied for the analysis of the HER2/neu
breast cancer marker. The anti-HER2/neu was biotinylated which made attachment to the
streptavidin modified particles easy. The direct detection method used in this study was simple
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and straightforward. Normal levels of HER2/neu in serum are < 10 ng/mL. The HER2/neu
assay had a limit of detection of 85 ng/mL and was only able to detect abnormal levels of
HER2/neu. We are currently developing a more sensitive assay that can rapidly and reliably
detect multiple breast cancer markers for potential use in clinical and academic laboratories.
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Chapter 4

Quantum Dot-Mesoporous Silica Microcomposites for Biomarker
Analysis
4.1 Abstract

Chapter 4 discusses the preparation and application of mesoporous silica particles
encoded with highly fluorescent CdSe/ZnS quantum dots as signal transducers for the
simultaneous detection of three different breast cancer markers. Breast cancer is the most
commonly diagnosed cancer in women. Early diagnosis of this disease has great prognostic
value, allows for patients to receive the correct treatment, and is particularly important for breast
cancer recovery and survival. The ability to screen for multiple biomarkers simultaneously
greatly reduces cost, diagnosis time, and improves prognosis. The current gold standards for
detecting breast cancer are fluorescence in situ hybridization (FISH) and immunohistochemistry
(IHC), neither of which can identify multiple biomarkers simultaneously. Both FISH and IHC
are invasive because they require a biopsy in order to provide a sample for analysis. The use of
quantum dot-mesoporous silica composite particles (SiQDs) to detect breast cancer proteins
offers several advantages over FISH and IHC.

A rapid and simple method for encoding

mesoporous silica particles with quantum dots for the minimally invasive, simultaneous
detection of the three most common breast cancer markers HER2/neu, ERa, and PR in bovine
serum is described. The method using SiQD is minimally invasive in that it requires a serum
sample that can be obtained by inserting a needle in the vein compared to removing breast tissue
via biopsy. The assay is based on the use of quantum dot-containing mesoporous silica particles
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as signal transducers. The normal level for HER2/neu in serum is < 10 ng/mL and <15 ng/mL
for ERa and PR. A direct detection and sandwich assay were employed to measure the levels of
breast cancer proteins in bovine serum. The direct detection method was the simpler of the two
and involves the nonspecific adsorption of protein to a glass well plate. This method was only
able to measure abnormal levels of protein. The HER2/neu assay had a limit of detection of 85
ng/mL. The ERa assay had a limit of detection of 100 ng/mL, and the PR assay had a limit of
detection of 200 ng/mL. The sandwich assay had approximately a 20 to 30-fold improvement in
detection and was able to detect both normal and abnormal levels of protein. The sandwich
assay was performed by covalently binding a capture antibody to the glass plate and using the
antibody labeled SiQDs as the detection. The HER2/neu sandwich assay was able to measure as
low as 3 ng/mL, 6ng/mL for ERa, and 11 ng/mL for PR. Multiplexed detection for the lowest
detectable levels for the sandwich assay was achieved. InP/ZnS quantum dots were also used to
detect the breast cancer markers.

Multiplexed detection was achieved using the InP/ZnS

encoded particles. The limits of detection of HER2/neu, ERa, and PR were 17 ng/mL, 25
ng/mL, and 32 ng/mL, respectively. The use of SiQDs as signal transducers could potentially be
used in the early diagnosis of breast cancer and can possibly be used to either replace or
complement FISH and IHC.

4.2 Introduction

In the United States one in eight women have breast cancer, and approximately 192,000
new cases of invasive breast cancer and 67,800 of noninvasive breast cancer will be diagnosed
this year.1,2 Besides lung cancer, breast cancer death rates are higher than those for any other
cancer. An estimated 40,500 women are expected to die from breast cancer this year.1, 2 Over
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the past two decades, death rates have decreased, and the outcome of patients with breast cancer
has improved. This improvement is due to advances in treatment and early diagnosis. Early
diagnosis is of great prognostic value and is particularly important for breast cancer recovery and
survival. Human epidermal growth factor receptor 2 (HER2/neu) and the steroid hormone
receptors estrogen receptor (ER) and progesterone receptor (PR) are the most commonly
amplified and overexpressed proteins in breast cancer. Detection of elevated HER2/neu , ER,
and PR expression can greatly improve the treatment and prognosis of breast cancer. It is
essential to be able to screen for all three breast cancer markers simultaneously.

Their

simultaneous detection greatly reduces time and cost, thus increasing the chances of early
diagnosis, improving prognosis, and providing information about the proper treatment. The
current gold standards for detecting breast cancer are fluorescence in situ hybridization (FISH)
and immunohistochemistry (IHC). Although FISH and IHC are most commonly used, both of
these methods have limitations including rapid photobleaching of the fluorophore, the inability to
screen for multiple breast cancer markers simultaneously, and invasiveness. These techniques
are also time consuming, labor intensive, and costly.3-8
FISH uses fluorescent probes that only hybridize to the region of the chromosome that
shows a highly similar sequence to the probe. A DNA probe is fluorescently labeled, denatured,
and then hybridized to specific DNA sequences on chromosomes. Scheme 4.1 shows the general
process of FISH. FISH is very accurate and highly sensitive with a limit of detection down to
the fmol/mg protein range. There are also some disadvantages. FISH is labor intensive and
takes days to complete.9-11 FISH analysis is expensive and requires highly skilled technicians.11
Another limitation is that the permeability of the tissue or cells of interest must be increased
without destroying the structural integrity of the cell or tissue. FISH uses fluorophores which are
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susceptible to rapid photobleaching, have various excitation wavelengths, and overlapping
emission peaks. The spectral overlap of the fluorophores does not allow simultaneous detection
of multiple fluorescent probes.

Scheme 4.1. General scheme of FISH. www.genome.gov

IHC uses fluorescently labeled antibodies to directly locate proteins in the cells of tissue.
The fluorescently labeled antibody specifically binds to the antigen of interest and can be
visualized using fluorescence microscopy. Scheme 4.2 shows the scheme of IHC. IHC has a
limit of detection comparable to that of FISH. It is also inexpensive and can be done easily with
simple training.12-14 Some limitations are that IHC is invasive, the fluorophores used are subject
to photobleaching, and simultaneous detection of antigens in the tissue section is not possible.
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Scheme 4.2. Scheme of IHC.

The minimally invasive application of quantum dot encoded mesoporous silica particles
as signal transducers in a multiplexed assay of the breast cancer markers HER2/neu, ERa, and
PR is described.

QDs have unique optical properties that offer several advantages over

conventional fluorophores including broad absorption spectra, narrow emission peaks, high
photostabilities, high emission quantum yields, large molar extinction coefficients, longer
fluorescence lifetimes, large Stokes shifts, and size dependent emission wavelength tunability.1526

The levels of HER2/neu in serum are < 10 ng/mL in normal patients and > 10ng/mL in breast

cancer patients.27, 28 The levels of ERa and PR in serum are > 15ng/mL in breast cancer patients.
It is essential to have a sensitive assay that can rapidly and reliably measure the levels of the
HER2/neu, ERa, and PR protein and gene in order to issue an accurate prognosis for treatment.
This rapid, simple, multiplexed technique offers several advantages to the gold standard methods
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and can possibly be used to either replace or complement the FISH and IHC. The multiplexed
detection of HER2/neu, ERa, and PR with SiQD entails immobilizing the antigen with a capture
antibody and adding antibody labeled SiQD to serve as the signal transducer.

4.3 Experimental

4.3.1 Synthesis of TOPO coated quantum dots

TOPO coated CdSe/ZnS quantum dots were prepared by a method developed by Peng
with slight modifications. Briefly, 12.7 mg cadmium oxide (CdO) and 160 mg lauric acid were
mixed in a 3-neck flask under nitrogen and heated to >200 °C to until the CdO was dissolved in
the lauric acid. A clear, colorless solution was formed. Then, 1.9 g of trioctylphosphine oxide
(TOPO) and 1.9 g hexadecylamine (HDA) were added to the solution under stirring and the
temperature was increased to 280°C for 10 min. Next, 80 mg selenium powder was dissolved in
2mL solution of trioctylphosphine (TOP) and was rapidly injected into the solution under
vigorous stirring. The mixture was cooled to ~200 °C and kept at this temperature for 3 minutes.
When the quantum dots reached the desired color, a ZnS shell was added as follows: a 2 mL
TOP solution containing 250 µL hexamethyldisilathiane ((TMS) S) were mixed with 1 mL
2

diethylzinc (Zn(Et) ) under nitrogen and then slowly injected into the solution. The reaction
2

mixture was kept at 180 °C for one hour. The solution was then cooled to room temperature and
the resulting TOPO coated CdSe/ZnS quantum dots were washed three times with methanol and
re-dissolved in chloroform.
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4.3.2 Synthesis of myristic acid coated quantum dots

Injection solution preparation: 0.3 mmol (87uL) of tris(trimethylsilyl)phosphine and 2.4 mmol
(397uL) of 1-octylamine were dissolved in 1016 uL octadecene (ODE) (1.5mL total volume) in a
glove box.
Synthesis Procedure: 0.6 mmol (0.1752g) of indium acetate, 1.8 mmol (0.4111g) of myristic
acid, and 5mL of ODE were loaded into a three-neck flask. The mixture was heated to 180 ºC
under argon flow, for 30 min. Then, the P(TMS)3/amine solution made in glove box was injected
rapidly into the hot reaction mixture and allowed to react for 60 min. For the growth of ZnS
shell, the reaction solution was cooled down to 150 ºC. Zinc stearate (0.1 M in ODE) and sulfur
(0.1 M in ODE) precursors (1.2 mL each) were added consecutively to the reaction flask with the
InP nano crystals, waiting for 10 min between each injection at 150 ºC. After that, the
temperature was increased to 230 ºC for 20 min to allow the growth of the ZnS shell. The
reaction was cooled down to room temperature. For purification, the nanocrystals were
precipitated with methanol and centrifuged. The precipitate was redissolved in chloroform.

4.3.3 Preparation of fluorescent mesoporous silica beads

Fluorescent silica particles were prepared by dispersing 2mg of C18 modified silica in 1
mL 1- butanol. Two hundred microliters of 1 µM 495 nm, 560 nm, or 655 nm quantum dots
were added to the solution. The mixture was incubated for 30 minutes, centrifuged (5500 rpm,
10min), and washed three times with ethanol.

4.3.4 Preparation of thiol-modified fluorescent mesoporous silica beads
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Thiol-modified fluorescent mesoporous silica beads were prepared according to a
previously described method.29,

30, 31, 33

Briefly, two milligrams of fluorescent silica particles

were dispersed in 10 mL 1-butanol.

To prepare thiol modified particles, 500 µL 3-

mercaptopropyl trimethoxysilane (MPTMS) were added to the solution. The particles were
separated by centrifugation (5500 rpm, 10min) and washed three times with ethanol. The
particles were then re-dispersed in 4 mL of phosphate buffer (PB) containing 0.1% BSA at pH
7.4.

4.3.5 Preparation of streptavidin-modified fluorescent mesoporous silica beads

Streptavidin-modified fluorescent mesoporous silica beads were prepared according to a
previously described method.32 One milliliter of thiol-modified fluorescent mesoporous silica
stock solution was added to 2mg streptavidin-maleimide in 5mL PB containing 0.1% BSA at pH
7.4. The mixture was incubated under gentle stirring for three hours at room temperature. The
streptavidin-labeled beads were separated by centrifugation (5500 rpm, 10min) and washed three
times with PB. The streptavidin-labeled fluorescent mesoporous silica beads were re-dispersed
in 4 mL PB and used immediately for biotin-avidin assays.

4.3.6 Preparation of anti- HER2/neu, anti-ERa, and anti-PR labeled fluorescent
mesoporous silica beads

Antibody labeled fluorescent mesoporous silica particles were prepared by mixing 1mL
streptavidin modified silica particles with 50 µg of biotinylated anti-HER2/neu, anti-ERa, and
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anti-PR per milliliter PBS, separately. The antibody labeled particles were incubated at room
temperature for two hours. The particles were separated by centrifugation (5500 rpm, 10min)
and washed three times with PBS at pH 7.4. The particles were then re-dispersed in 4 mL of
PBS at pH 7.4 and immediately used for binding assays. Figure 4.1 is the schematic of the
preparation of antibody labeled particles used for direct detection.
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Mesoporous silica with embedded 545 nm and 655 nm
QDs
Biotinylated Anti-HER2/neu
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Figure 4.1. Anti-HER2/neu modified fluorescent silica particles for detection of HER2/neu. (a) the
reactive methoxy groups are hydrolyzed upon addition of water, (b) condensation covalently links the silane to the
oxide surface of quantum dot encoded mesoporous silica particles, (c) streptavidin is covalently bound to the silica
particles via thiol-maleimide chemistry, (d) biotinylated HER2/neu is added and bound to streptavidin modified
particles, and (e) direct detection assay performed.

4.3.7 Preparation of HER2/neu, ERa, and PR coated 96-well plate

For direct detection, a glass bottom 96-well plate was coated separately with HER2/neu,
ERa, and PR protein through nonspecific adsorption by adding 100 µL HER2/neu, ERa, and PR
protein in serum in PBS at varying concentrations. For sandwich detection, carboxylic acid
modified plates were incubated separately with 300 µL of a PBS solution containing 40mM 1Ethyl-3-[3-dimethylaminopropyl]carbodiimide

hydrochloride

(EDC)/5mM

N

–

hydroxysulfosuccinimide (sulfo-NHS) and 100 µL of 6 µg/mL anti-HER2/neu, anti-ERa, and
anti-PR capture antibodies. Each concentration of protein was added to three wells. The plate
was incubated for 20 hrs at 4°C.

Unoccupied sites were blocked by adding 300 µL of

Superblock T20 PBS buffer. Separately, one hundred microliters of anti- HER2/neu, anti-ERa,
and anti-PR labeled silica particles were added and incubated for 2 hours. The plate was washed
with PBS containing 0.05% Tween-20 and dried under a stream of nitrogen.

4.3.8 Characterization of the fluorescent mesoporous silica particles in solution and
attached to the 96-well glass plate:

58

4.3.8.1 Fluorescence emission spectra

Fluorescence emission measurements were performed using a SpectraMax M2
microplate reader (Molecular Devices, Inc.) equipped with a Xenon flash lamp source and a
photomultiplier (R-3896) detector.

4.3.8.2 Digital fluorescence imaging microscopy

Fluorescence images of the silica particles in solution and attached to the glass plate were
taken using a digital fluorescence imaging microscopy system that contained and Olympus IX71
inverted fluorescence microscope equipped with a 100 W mercury lamp as a light source and a
high performance color CCD camera (Olympus DP 70). The fluorescence images were obtained
through a 20x microscope objective using a filter cube containing a 425 ±20 nm band-pass
excitation filter, a 465 nm dichroic mirror, and a 475nm long pass emission filter. The software
DP controller was used for image analysis.

4.4 Results and Discussion

4.4.1 Direct assay for the detection of the breast cancer marker HER2/neu
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The surface of the 3µm mesoporous silica particles were functionalized with thiol groups
because thiol is a reactive functional group that allows the covalent coupling of maleimide
modified biomolecules through the formation of thio-ether bonds. Maleimide-streptavidin was
attached to the surface of the fluorescent mesoporous silica particles in order to couple the biotin
labeled anti-HER2/neu through streptavidin-biotin interactions. A direct detection assay was
developed by nonspecifically adsorbing the HER2/neu protein to the surface of the glass well
plate, adding the anti-HER2 labeled fluorescent silica particles to the plate, and averaging the
number of fluorescent particles in 20 randomly selected fields of view.

Figures 4.2 and 4.3

demonstrate the dependence of the binding of the fluorescent anti-HER2/neu labeled particles on
the concentration of HER2/neu. At concentrations of 0 µg/mL and 65 ng/mL, there were no
particles attached to the glass slide. There were also no particles for unlabeled particles with 10
µg/mL HER2/neu nor with anti-HER2/neu labeled particles added to 50 µg/mL and 10 µg/mL of
ERa and PR, respectively. The number of particles attached to the glass plate increased from 11
± 8 to 70 ± 11 when the concentration of HER2/neu increased from 85 ng/mL to 10 µg/mL. The
limit of detection for this direct assay was 85 ng/ml and the response was linear over the range of
HER2/neu concentrations studied (85 ng/mL and 10 µg/mL).

This assay was very reproducible

yielding similar results for three separate experiments.
To test the reproducibility of the assay when multiple wells are prepared in advance,
seven wells of the microplate were incubated with 10 µg/mL of HER2/neu. Measurements were
taken for seven days. For each day, one well of the HER2/neu coated glass plate was incubated
with anti-HER2/neu labeled fluorescent mesoporous silica particles. The standard procedure to
perform the assay was carried out and measurements were taken. Figure 4.4 shows that from day
1 to day 7 the fluorescence intensity decreased by 80%. The decrease in fluorescence intensity
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indicates that although the fluorescent silica beads are stable, HER2/neu adsorbed to the plate
loses activity daily when the plates are prepared in advanced. The direct assay should be
performed immediately after the plate preparation in order to achieve the optimal fluorescence
signal. The assay was highly reproducible when new plates are prepared.
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Figure 4.2. Dependence of the binding of the fluorescent anti-HER2/neu labeled particles on the concentration of
HER2/neu exposed to the glass well plate before addition of the antibody labeled beads: plot of mean number of
particles attached to glass versus HER2/neu concentration.

61

Figure 4.3. Dependence of the binding of the fluorescent anti-HER2/neu labeled particles on the concentration of
HER2/neu exposed to the glass well plate before addition of the antibody labeled beads: (a) digital fluorescence
microscopy images of unlabeled anti-HER2 silica with 10 µg/mL HER2/neu, (b) 0 µg/mL HER2/neu, (c) 10 µg/mL
PR, (d) 50 µg/mL ERa, (e) 65 ng/mL HER2/neu, (f) 85 ng/mL HER2/neu, (g) 0.1 µg/mL HER2/neu, (h) 2 µg/mL
HER2/neu, (i) 5 µg/mL HER2/neu, and (j) 10 µg/mL HER2/neu.
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Figure 4.4. Stability of HER2/neu plate prepared in advance (a) 545 nm quantum dots in silica and (b) 655 nm
quantum dots in silica.

4.4.2 Detection of ERa

The assay was performed using the same approach as for the HER2/neu assay but uses
496 nm QD instead of 560 nm. The limit of detection for ERa was 100 ng/mL, and the response
was linear over the range of HER2/neu concentrations studied (100 ng/mL and 50 µg/mL).
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Figures 4.5 and 4.6 show the increase of the number of particles attached to the glass bottom
plate with increasing ERa concentration. ERa was first added to the plate, the plate was then
washed, and then the anti- ERa labeled beads were added.

At concentrations of 0 µg/mL and

85 ng/mL, there were no particles attached. There were also no particles for unlabeled particles
with 50 µg/mL ERa, nor with anti-ERa labeled particles added to 10 µg/mL and 10 µg/mL of
HER2/neu and PR, respectively.

The number of particles attached to the glass per image

increased from 10 ± 9 to 88 ± 6 when the concentration of ERa increased from 100 ng/mL to 50
µg/mL.
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Figure 4.5. Dependence of the binding of the fluorescent anti-ERa labeled particles on the concentration of ERa
exposed to the glass well plate before addition of the antibody labeled beads: plot of mean number of particles
attached to glass versus ERa concentration.
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Figure 4.6. Dependence of the binding of the fluorescent anti-ERa labeled particles on the concentration of ERa (a)
digital fluorescence microscopy images of unlabeled anti- ERa silica with 50 µg/ml ERa, (b) 0 µg/ml ERa, (c) 85
ng/ml ERa, (d) 10 µg/ml HER2/neu, (e) 10 µg/ml PR, (f) 100 ng/ml ERa, (g) 2 µg/ml ERa, (h) 5 µg/ml ERa, and (i)
10 µg/ml ERa, and (j) 50 µg/ml ERa.
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4.4.3 Detection of PR

The limit of detection for PR was 200 ng/mL , and the response was linear over the range
of HER2/neu concentrations studied (200 ng/mL and 10 µg/mL). The emission wavelength of
QD was 655 nm. Figures 4.7 and 4.8 show an increase of the number of particles attached with
increasing PR concentration exposed to the glass. At concentrations of 0 µg/mL and 100 ng/mL,
there were no particles attached. There were also no particles attached for unlabeled particles
with 10 µg/mL PR, nor with anti-PR labeled particles added to 50 µg/mL and 10 µg/mL of ERa
and HER2/neu, respectively. The number of particles attached to the glass increased from 10 ±
4 to 60 ± 9 when the concentration of ERa increased from 200 ng/mL to 10 µg/mL.
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Figure 4.7. Dependence of the binding of the fluorescent anti-PR labeled particles on the concentration of
PRexposed to the glass well plate before addition of the antibody labeled beads: plot of mean number of particles
attached to glass versus PR concentration.
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Figure 4.8. Dependence of the binding of the fluorescent anti-PR labeled particles on the concentration of PR: (a)
digital fluorescence microscopy images of unlabeled anti- PR silica with 10 µg/ml PR, (b) 0 µg/ml PR, (c) 100
ng/ml ERa, (d) 10 µg/ml HER2/neu, (e) 50 µg/ml ERa, (f) 200 ng/ml PR, (g) 500 ng/mL, (h) 1 µg/ml PR, (ij) 2
µg/ml PR, (j) 5 µg/ml PR, and (k) 10 µg/ml PR.
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4.4.4 Sandwich Detection of HER2/neu, ERa, and PR

The sandwich detection assay was performed in order to improve the limit of detection of
the breast cancer markers. The sandwich technique is more sensitive in that it involves the use of
two antibodies to detect the antigen. The capture antibody was covalently bound to a carboxylic
acid modified glass plate via EDC/sulfo-NHS chemistry. Using both EDC and sulfo-NHS
produces a more stable amide bond than using EDC alone. EDC reacts with a carboxyl to form
an unstable amine-reactive o-acylisourea intermediate. If this intermediate does not encounter an
amine, it will hydrolyze and regenerate the carboxyl group. In the presence of sulfo-NHS, EDC
can be used to convert carboxyl groups to amine-reactive sulfo-NHS esters.

This is

accomplished by mixing the EDC with the carboxyl containing glass plate, adding Sulfo-NHS,
and the capture antibody. Separately, varying concentrations of HER2/neu, ERa, and PR were
then added and allowed to bind to the capture antibodies on the plate. The plate was then
washed and the antibody labeled SiQDs were added.

Figure 4.9 shows the fluorescence

microscope images of the bound anti-HER2/neu modified beads after the activation of the
HER2/neu capture antibody with EDC/sulfo-NHS to bind to amino-modified plates and the
activation of a carboxylic acid- modified plate with EDC/sulfo-NHS to bind to the capture
antibody. The concentration of HER2/neu was 10µg/mL. The image where the capture antibody
is bound to the amino-modified plate shows a high degree of aggregation; whereas, the image of
the capture antibody bound to the carboxylic modified plate showed substantially less
aggregation. The aggregation in Figure 4.9a is due to the cross-linking of the –NH2 groups of
one antibody to the –COOH groups of a neighboring antibody. Aggregation is reduced by
activating the plate instead of the antibody to eliminate any cross-linking. Figure 4.10 shows
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that the sandwich assay yields approximately 100 times more captured particles than the direct
detection assay under the same conditions.

Figure 4.9. Fluorescence microscope images of a) EDC/sulfo-NHS activated capture HER2/neu antibody bound to
amino-modified glass plate and b) EDC/sulfo-NHS activated carboxylic acid modified glass plate bound to amino
groups of capture HER2/neu antibody.

Figure 4.10. Fluorescence microscope images of a) sandwich assay with 10µg/mL HER2/neu and b) direct detection
assay with 10µg/mL HER2/neu.

The normal levlels for HER2/neu in serum is < 10 ng/mL and < 15 ng/mL for ERa and
PR. The direct assay was only able to detect abnormal levels of breast cancer proteins. It is
essential to be able to detect both normal and abnormal levels of breast cancer proteins for
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diagnostic and prognostic reasons. The negative controls (data not shown) were the same as
those for the direct detection and showed no particles attached to the glass plate. Figures 4.11
and 4.12 show the number of attached particles observed per image as a function of antigen
concentration exposed to the well. The highest concentrations used for the sandwich assay were
the limit of detection values for the direct assay. The average number of particles attached to the
glass plate increased from 12 ± 2 to 150 ± 8 when the concentration of HER2/neu increased from
3 ng/mL to 85 ng/mL. The limit of detection of the direct assay was 3 ng/mL.
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Figure 4.11. Dependence of the binding of the fluorescent anti-HER2/neu labeled particles on the concentration of
HER2/neu: plot of mean number of particles attached to glass versus HER2/neu concentration.
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Figure 4.12. Dependence of the binding of the fluorescent anti-HER2/neu labeled particles on the concentration of
HER2/neu: (a) digital fluorescence microscopy images of anti-HER2 silica with 85 ng/mL HER2/neu, (b) 25ng/mL
HER2/neu, (c) 15 ng/mL HER2/neu, (d) 10 ng/mL HER2/neu, (e) 4 ng/mL HER2/neu, and (f) 3 ng/mL HER2/neu.

The limit of detection for ERa was 6 ng/mL. Figures 4.13 and 4.14 show the increase of
the number of particles attached to the glass bottom plate with increasing ERa concentration.
The number of particles attached to the glass increased from 14 ± 8 to 210 ± 11 when the
concentration of ERa increased from 6 ng/mL to 100 ng/mL.
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Figure 4.13. Dependence of the binding of the fluorescent anti-ERa labeled particles on the concentration of ERa:
plot of mean number of particles attached to glass versus ERa concentration.
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Figure 4.14. Dependence of the binding of the fluorescent anti-ERa labeled particles on the concentration of ERa:
(a) digital fluorescence microscopy images of anti- ERa silica with 100 ng/mL ERa, (b) 25 ng/mL ERa, (c) 15
ng/mL ERa, (d) 10 ng/mL ERa, and (e) 6 ng/mL ERa.

The limit of detection for PR was 11 ng/mL. Figures 4.15 and 4.16 show an increase of
the number of particles attached with increasing PR concentration. The number of particles
attached to the glass increased from 11 ± 6 to 195 ± 8 when the concentration of ERa increased
from 11 ng/mL to 200 ng/mL.

The sandwich assay had approximately a 20 to 30-fold
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improvement in detection limit compared to the direct detection method and was able to detect
both normal and abnormal levels of protein.
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Figure 4.15. Dependence of the binding of the fluorescent anti-PR labeled particles on the concentration of PR: plot
of mean number of particles attached to glass versus PR concentration.
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Figure 4.16. Dependence of the binding of the fluorescent anti-PR labeled particles on the concentration of PR: (a)
digital fluorescence microscopy images of anti- PR silica with 200 ng/mL PR, (b) 25 ng/mL PR, (c) 15 ng/mL PR,
(d) 12 ng/mL PR, and (e) 11 ng/mL PR.

4.4.5 Multiplexed Analysis of HER2/neu, ERa, and PR

For the multiplexed analysis of HER2/neu, ERa, and PR, a mixture of the biomarkers
were added to the well plate and the assay was performed like the individual sandwich assays.
The limit of detection concentrations from the individual assays were used in the multiplexed
analysis. One hundred microliters each of 4 ng/mL HER2/neu, 6 ng/mL ERa, and 11 ng/mL PR
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were added. One hundred microliters of each antibody labeled silica particle were then added
and the plate was analyzed as described previously.

Figure 4.17 shows the fluorescence

microscope images of a mixture of HER2/neu, ERa, and PR and the fluorescence spectrum of
the emission wavelengths of all three fluorescently labeled silica particles in a mixture. The
presence of biomarkers can easily be determined by the different colors corresponding to the
particular antigens. The simultaneous detection of all three biomarkers using the SiQD is
advantageous over FISH and IHC because neither method can multiplex.

Figure 4.17. Multiplexed detection of (a) 3 ng/mL HER2/neu, 6 ng/mL ERa, and 11 ng/mL PR and (b) the
fluorescence spectrum of 495 nm, 560 nm, and 655 nm SiQDs.
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4.4.6 Sandwich assay with InP/ZnS quantum dots

As mentioned in Section 1.4.2, CdSe/ZnS quantum dots have limited use in biological
applications because of their toxicity and are environmentally restricted. InP/ZnS have low
toxicity and would be a good alternative to use in biological and environmental applications.
Therefore, 485 nm, 550 nm, and 620 nm InP/ZnS have been incorporated into mesoporous silica
particles to demonstrate their capabilities as signal transducers for the individual and multiplexed
detection of HER2/neu, ERa, and PR, respectively. The limit of detection for HER2/neu was 17
ng/mL. Figure 4.18 shows the fluorescence microscope images of the increase of the number of
particles attached to the glass plate with increasing HER2/neu concentration. The limit of
detection for ERa was 25 ng/mL. Figure 4.19 shows the fluorescence microscope images of the
increase of the number of particles attached to the glass plate with increasing ERa concentration.
The limit of detection for PR was 32 ng/mL. Figure 4.20 shows the fluorescence microscope
images of the increase of the number of particles attached to the glass bottom plate with
increasing PR concentration.

Figure 4.21 shows the fluorescence microscope images of a

mixture of HER2/neu, ERa, and PR. The mixture contained the limit of detection concentrations
of 17 ng/mL HER2/neu, 25 ng/mL ERa, and 32 ng/mL PR. The limits of detection for the
sandwich assay using the InP/ZnS quantum dots were inferior to that of CdSe/ZnS. The InP/ZnS
encoded silica particles were only able to detect abnormal levels of the breast cancer markers.
The higher limits of detection are directly related to the disadvantages of InP/ZnS compared to
CdSe/ZnS quantum dots, the most obvious one being poor fluorescence quantum yield. The
sandwich assay using InP/ZnS quantum dots was able to detect approximately four times better
than the direct assay using the CdSe/ZnS quantum dots. The limits of detection for HER2, ERa,
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and PR for the sandwich assay using CdSe/ZnS quantum dots were (3, 6, and 11) ng/mL,
respectively; and, (17, 25, and 32) ng/mL for the InP/ZnS quantum dots. CdSe/ZnS typically
have quantum yields that are = 75%. To date, the highest quantum yield achieved for InP/ZnS is
40%.

Figure 4.18. Sandwich detection of HER2/neu with InP/ZnS QDs of (a) 17 ng/mL HER2/neu, (b) 25
ng/mL HER2/neu, and (c) 50 ng/mL HER2/neu.

Figure 4.19. Sandwich detection of ERa with InP/ZnS QDs of (a) 25 ng/mL ERa, (b) 40 ng/mL ERa, and
(c) 50 ng/mL ERa.
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Figure 4.20. Sandwich detection of PR with InP/ZnS QDs of (a) 32 ng/mL PR, (b) 40 ng/mL PR, and (c) 50
ng/mL PR.

Figure 4.21. Multiplexed detection of (a) 17 ng/mL HER2/neu, 25 ng/mL ERa, and 32 ng/mL PR.

4.5 Summary and Conclusions
The ability to specifically, rapidly, and reliably detect cancer markers is important and in
high demand.

The assay in this study was based on the use of quantum dot-containing

mesoporous silica particles as signal transducers which identified and quantified the amount of
HER2/neu, ERa, and PR present. We have successfully prepared anti-HER2/neu, anti-ERa, and
anti-PR labeled fluorescent mesoporous silica particles to detect the breast cancer markers in
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serum. The antibodies were biotinylated which made attachment to the streptavidin modified
particles easy. The direct detection method used in this study was simple but only able to detect
abnormal levels of breast cancer markers. The HER2/neu assay had a limit of detection of 85
ng/mL. The ERa assay had a limit of detection of 100 ng/mL, and the PR assay had a limit of
detection of 200 ng/mL. Simultaneous detection of the three markers was achieved. The direct
assay should be performed immediately after plate preparation in order to achieve the optimal
fluorescence signal. The sandwich detection assay was performed in order to improve the limit
of detection of the breast cancer markers. The sandwich assay could detect both normal and
abnormal levels of breast cancer markers. There was a 20 to 30-fold improvement in the
detection of the breast cancer markers with this technique. The detection limits for HER2/neu,
ERa, and PR were 3 ng/mL, 6ng/mL and 11 ng/mL, respectively. The sandwich assay using
InP/ZnS quantum dots were able to detect (17, 25, and 32) ng/mL of HER2/neu, ERa, and PR,
respectively. The higher detection limits are due to the poor quantum yield compared to that of
CdSe/ZnS quantum dots. More studies to improve the properties of InP/ZnS quantum dots are
needed in order to have optical properties superior to CdSe/ZnS quantum dots. These quantum
dot encoded particles could potentially be used in the early detection of HER2/neu, ERa, or PR
positive breast cancer. Unlike FISH and IHC, this technique was capable of analyzing all three
biomarkers simultaneously which would reduce diagnosis time and improve prognosis. This
technique is also a better candidate than FISH and IHC for early diagnosis in that serum levels
can be monitored without the presence of a tumor. This is important for the recovery and
survival of breast cancer patients. The invasive techniques of FISH and IHC analyze breast
tissue samples from regions of interest usually where a tumor has been detected. By the time the
tumor is detected, the probability of proliferation or metastasis is increased significantly. By

80

simply using the minimally invasive technique of collecting serum samples, the use of SiQDs as
signal transducers could potentially be used in the early diagnosis of breast cancer and can
possibly be used to either replace or complement FISH and IHC.
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Chapter 5

Enzymatic Release of Fluorescent Drug Analogue from Human
Serum Albumin Nanoparticles
5.1 Abstract

Chapter 5 discusses the application of magnetic, fluorescent human serum albumin
(HSA) nanoparticles that were prepared using the desolvation method. The HSA nanoparticles
used in this study had an average diameter of ~ 100 nm.

The HSA particles were loaded with

10 nm PEG coated magnetite particles and the fluorescent drug analogue, BOPIPY-vinblastine.
This paper describes the effect of matrix metalloproteinase (MMP) concentration on the release
of drug analogue from the composite particles. The MMPs used were collagenase and MMP-11.
With higher doses of collagenase, the release of the drug was complete within 24 hours; whereas,
the release was still not complete after 48 hours with the highest does of MMP-11 studied.
These magnetic, fluorescent particles could also potentially be used as a theranostic tool in that
the particles can detect the diseased site, image using MRI, release drug upon heating by
magnetic field, and magnetic hyperthermia.

5.2 Introduction

Conventional chemotherapy involves the nonspecific action of the drug on normal tissue
which causes toxic, deleterious side effects. The toxic side effects occur because there is no
specific targeting of the drug to only diseased tissue. The controlled release and targeting of
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drug agents specifically to diseased sites are of major interest in cancer research.1-5 This
approach would allow for smaller doses to be administered and would significantly reduce the
toxicity to normal cells. Nanoparticles have the advantages of good stability, high drug loading
efficiency, minimal drug leakage, and preferential accumulation in tumors.6-8 Nanoparticlebased drug delivery systems have exhibited great success at both targeting and controlled release.
Recently, Mirkin, Lippard, and coworkers developed a DNA-gold nanoparticle conjugate system
to bind to the Pt(IV) prodrug, Cisplatin, to monitor its uptake and efficacy in multiple cancer cell
lines.9 It was shown that the Pt-DNA-gold nanoparticle conjugates were more effective than free
cisplatin at killing the cancer cells. Linden and coworkers demonstrated the use of mesoporous
silica nanoparticles for the targeted intracellular delivery of hydrophobic model drug
fluorophores to cancer cells.10 The mesoporous silica nanoparticles were able to specifically
release two hydrophobic fluorophores into the endosomes of cancer cells. The fluorophores were
subsequently released into the cytoplasm which is critical for good drug efficacy. Briesen and
coworkers used antibody labeled human serum albumin (HSA) nanoparticles to specifically
target and release the anti-cancer drug doxorubicin to HER2 positive breast cancer cells.11 It was
shown that the antibody labeled HSA particles loaded with doxorubicin were significantly more
effective at killing the cancer cells than doxorubicin loaded particles labeled with a nonspecific
antibody.
HSA is the most abundant blood plasma protein whose functions include transporting
hormones12, fatty acids13, and drugs.14 HSA is inexpensive, and the preparation of HSA
nanoparticles is simple and reproducible. HSA nanoparticles as drug carriers are very attractive
because they are biocompatible, biodegradable, nontoxic, nonimmunogenic and contain
functional groups on the surface which allow for covalent linkage of biomolecules.15-18
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Spankuch and coworkers loaded anti-HER2 labeled HSA nanoparticles with antisense
oligonucleotides (ASO) to specifically target breast cancer cells.19 It was found that the ASO
labeled particles significantly reduced the gene expression of an overexpressed mitotic regulator.
In 2005 the Food and Drug Administration (FDA) approved Abraxane, the first ever drug carrier
system based on 130 nm HSA nanoparticles as transporters for the water insoluble
chemotherapeutic agent, paclitaxel. Paclitaxel is used to treat breast, ovarian, and lung cancers.20
HSA nanoparticles show much higher intratumoral concentrations, higher anti-tumor activity,
and less adverse side effects than the traditional Cremophor-based paclitaxel delivery.21-24
In this paper we describe the preparation and in vitro application of magnetic, fluorescent
HSA nanoparticles for the targeting and controlled release (as a function of enzyme
concentration) of the fluorescent cancer drug analogue BODIPY vinblastine.

Matrix

metalloproteinases (MMPs) are a large family of proteolytic enzymes that are responsible for the
degradation of the basement membrane and extracellular matrix and play a role in apoptosis and
angiogenesis.35-37 MMP overexpression in tumors is largely responsible for tumor invasion and
metastisis.38-40 MMPs are composed of four main subgroups: the collagenases, geletinases,
stromelysins, and membrane MMPs. In this study, collagenase and MMP-11 (stromelysin-3)
were used to study the enzymatic activity on the magnetic, fluorescent HSA nanoparticles.
Collagenase is an enzyme that cleaves peptide bonds in collagen but also has a wide
range of proteolytic activity that is not specific to only collagen. MMP-11 is unique from other
MMPs in that it does not degrade the extracellular matrix.41, 42 It cleaves the serine proteinase
inhibitor a1-proteinase. MMP-11 is also unique in that it is not expressed in normal tissue, but is
present in the majority of the stromal cells which surround the cancer cells in invasive tumors.43,
44
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Previously our group has studied the release (as a result of an oscillating magnetic field)
of the drug analog, dextran-tetramethylrhodamine, from magnetic collagen gels.25 We also used
iron oxide nanoparticles coated with luminescent quantum dots and labeled with anitibodies to
detect and separate breast cancer cells in serum.26 Vinblastine is a plant derived chemotherapy
drug used to treat a number of cancers including lymphoma, testicular, non-small cell lung,
cervical, and breast cancers.27, 28 It functions as a mitotic inhibitor that binds to tubulin in the
mitotic spindle. Vinblastine inhibits microtubule formation which causes mitotic arrest and
death of tumor cells.29 It also acts to inhibit drug efflux mediated by P-glycoprotein in multidrug
- resistant cells.30 As with several anti-cancer drugs, vinblastine has toxic side effects and poor
water solubility. The use of HSA nanoparticles, which preferentially bind hydrophobic drugs,
can alleviate these issues.

Incorporating magnetic iron oxide nanoparticles offers several

advantages. The iron oxide particles can be used to magnetically target the HSA complex to
diseased sites31, image the drug loaded particles using magnetic resonance imaging (MRI)32, and
act as a mechanism to kill cancer cells by magnetic hyperthermia.33 The magnetic, drug-loaded
HSA nanoparticles have the potential to revolutionize the future of cancer therapy.

5.3 Experimental

5.3.1 Preparation of magnetic BODIPY-Vinblastine encoded HSA nanoparticles

HSA particles were prepared using a well established desolvation technique.16, 34 20 mg
of HSA were dissolved in 1 mL of purified water and the pH was adjusted to 8.2 with 10 mM
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NaOH. One hundred microliters of 100 nM BODIPY-vinblastine and 25 µL of 1 µM PEG coated
Fe3O4 were added to the HSA solution. The solution was stirred constantly at 650 rpm at room
temperature for 2 h. Three milliliters of ethanol were added at a rate of 1 mL/min with a
peristaltic pump. 8% glutaraldehyde was added (1.175 µL/mg HSA) and the solution was stirred
constantly for 24 h. The solution was then centrifuged three times at 13,000 g for 12 minutes
and redispersed in 1 mL of DI water.

5.3.2 Preparation of Anti-PR labeled HSA particles
Antibody labeled magnetic fluorescent HSA particles were prepared by mixing 1 mL
HSA composite particles (prepared as described above) with 50 µg of anti-PR / mL PBS
containing 40 mM EDC/5 mM sulfo-NHS. The antibody labeled particles were incubated under
gentle stirring at room temperature for two hours. The particles were separated by centrifugation
(13,000g, 12min) and washed three times with PBS at pH 7.4. The particles were then redispersed in 4 mL of PBS at pH 7.4 and immediately used for binding assays.

5.3.3 Direct detection of PR
For direct detection, a 96-well plate was coated with 100 µL bovine serum spiked with 10
µg/mL PR protein through nonspecific adsorption. The plate was incubated for 20 hrs at 4°C.
Unoccupied sites were blocked by adding 300 µL of Superblock T20 PBS buffer. One hundred
microliters of anti-PR labeled HSA composite particles were added and incubated for 2 hours.
The plate was washed with PBS containing 0.05% Tween-20 and dried under a stream of
nitrogen.

To measure the release of BODIPY-vinblastine, 300 µL of PBS buffer pH 7.4

containing varying concentrations of collagenase and MMP-11 were added to the wells. At
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different time intervals ranging from 0 hours to 48 hours, 200 µL aliquots of the sample were
taken and the fluorescence intensity was measured using a microplate reader.

5.3.4 Characterization of unloaded HSA particles
Cryo-TEM images were taken with a JEOL 2011 TEM at 120 kV. The image
magnifications were 50,000 x for 1 micron HSA and 12,000 x for 100 nm HSA particles.

5.4 Results and Discussion

5.4.1 Characterization of unloaded HSA particles

Figure 5.1 shows the cryo-TEM images of a) 1 micron HSA particles and b) 100 nm
HSA particles. The particles have a well defined speherical shape and are monodisperse. The
scale bar for a) is 20 nm and b) 100 nm.

Figure 5.1. Cryo-TEM images of a) 1 micron HSA and b) 100 nm HSA.
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Figure 5.2 shows images of 100 nm magnetic BODIPY-Vinblastine encoded HSA
particles suspended in aqueous buffer. The percent entrapment of BODIPY-vinblastine and
Fe3O4 in HSA was calculated to be 69% and 16%, respectively. The values were calculated
using the equation:
(C-c)/C x 100

(1)

Where C is the initial concentration of fluorophore and magnetic particles added and c is the
concentration of the supernatant after cross linking of HSA.
The images were taken in room light and under UV radiation to show the magnetic and
fluorescent properties of the composite particles. The particles were placed in a sample vial and
mounted in front of a strong magnet. After 15 minutes, the magnetic/fluorescent HSA particles
were completely separated from the solvent.
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Figure 5.2. Images of a) HSA nanoparticles at t = 0 min in room light, b) HSA nanoparticles at t = 15 min in room
light, c) HSA nanoparticles at t = 0 min under UVlight, and d) HSA nanoparticles at t = 15 min under UV light.

5.4.2 Effect of enzyme concentration on the release of BODIPY-Vinblastine from HSA
nanoparticles
Figures 5.3 and 5.4 show the release rates of BODIPY-vinblastine in the presence of
collagenase and MMP-11. After the anti-PR labeled HSA particles attached to the antigen and
the plate was washed, varying concentrations of collagenase and MMP-11 were added.
Fluorescence intensity measurements (F/Fo) were taken at 0, 2, 6, 8, 24, 32, and 48 hours after
addition of the enzyme to the HSA particles. The excitation wavelength was ? ex = 375 nm and
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the emission wavelength was ? em = 515 nm. As the concentration of enzyme increased, the rate
of BODIPY-vinblastine release from the HSA nanoparticles increased. Concentrations of
collagenase and MMP-11 ranged from 0 to 10 µg/mL. The release of BODIPY-vinblastine was
complete within 24 hours with a collagenase concentration of 10 µg/mL. However, the release
of BODIPY-vinblastine was not complete within 48 hours with 10 µg/mL MMP-11. The slow
proteolytic cleavage with MMP-11 is consistent with reports that MMP-11 has very low
proteolytic activity in vitro.45

Figure 5.3. Effect of collagenase concentration on BODIPY-vinblastine release from HSA nanoparticles. a) 10
µg/mL collagenase, b) 8 µg/mL collagenase, c) 6 µg/mL collagenase, d) 2 µg/mL collagenase, e) 0 µg/mL
collagenase, and f) unlabeled HSA particles with 10 µg/mL collagenase.
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Figure 5.4. Effect of MMP-11 concentration on BODIPY-vinblastine release from HSA nanoparticles. a) 10 µg/mL
MMP-11, b) 8 µg/mL MMP-11, c) 6 µg/mL MMP-11, d) 2 µg/mL MMP-11, e) 0 µg/mL MMP-11, and f) unlabeled
HSA particles with 10 µg/mL MMP-11.

5.4.3 Control experiment for the release of BODIPY Vinblastine from HSA

To ensure that the enzyme is in fact degrading the HSA particles and releasing the
material in solution, 8 µg/mL of MMP-11 was added to five solutions of magnetic, fluorescent
particles without anti-PR on the surface. After various exposure times, the solution was placed
near a magnet for separation, and the fluorescence intensities of the supernatants were measured.
Each solution was measured at different time points. Figure 5.5 shows the fluorescence spectra
and a corresponding plot of fluorescence intensity vs time for the release of BODIPY vinblastine from HSA nanoparticles. The solution without any MMP-11 added showed no
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fluorescence in the supernatant (data not shown). At 0 hours of incubation with MMP-11, there
was very little fluorescence signal. The fluorescence intensity continued to increase from 6 to 32
hours. The increase in fluorescence intensity of the supernatants indicates enzyme degradation
of the HSA particles.

Because there is no antibody present, the possibility of antibody

degradation initiating the release of non- degraded particles in solution is ruled out.

Figure 5.5. Effect of MMP-11 concentration of BODIPY-vinblastine release from HSA nanoparticles suspended in
solution. a) fluorescence spectra and b) corresponding plot of the fluorescence intensity of supernatant as a function
of enzyme degradation time

5.4.4 Determination of BODIPY Vinblastine encapsulation in HSA nanoparticles

To determine whether BODIPY was encapsulated inside the HSA particles and not on the
surface, varying concentrations of KBr were added and the quenching effects were determined
by measuring the decrease in fluorescence intensity. Figure 5.6 shows the Stern-Volmer plot of
free BODIPY and BODIPY encapsulated in HSA. F0 represents the fluorescence intensity of
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BODIPY in the absence of KBr, and F represents the fluorescence intensity in the presence of
KBr.

The plot for free BODIPY shows a very linear response (R2 = 0.9985) as a function of

KBr concentration. According to the Stern-Volmer equation F0/F = K[Q] + 1, where K is the
Stern-Volmer constant and Q is the quencher concentration, K (determined by the slope) for free
BODIPY is 3.18 M-1.

This clearly indicates one fluorophore population that is entirely

accessible to quencher. The plot for BODIPY encapsulated in HSA shows a nonlinear response
that curves downward towards the x-axis. This downward curvature suggests the presence of
two fluorophore populations: one with BODIPY on the surface and one buried inside the HSA.
The population on the surface is easily accessible to KBr quenching; whereas, the population
inside HSA is not. The downward curvature clearly indicates that BODIPY is entrapped inside
the HSA. This is important because it can be released specifically upon enzyme degradation of
the HSA particles in diseased tissue which eliminates any premature release.

Figure 5.6. Stern-Volmer plot of fluorophore poulations. a) Free BODIPY and b) BODIPY inside HSA
nanoparticles
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5.5 Summary and Conclusions

HSA nanoparticles loaded with magnetite particles and a fluorescent drug analogue,
BODIPY- vinblastine were prepared. The method of preparing the HSA composite particles was
simple and reproducible. HSA has several advantages including the availability of surface
functional

groups

for

covalent

attachment

of

biomolecules,

biocompatibility,

and

biodegradability. This study showed, in vitro, the release of the drug analogue as a function of
enzyme concentration. Collagenase was superior at degrading the HSA particles compared to
MMP-11. The release was complete within 24 hours. It was proven that the enzymes do
degrade HSA and that BODIPY was successfully encapsulated inside the particles and not just
on the surface. The incorporation of magnetic particles into HSA makes them candidates for
theranostics. The antibody – labeled composite particles could be used to detect diseased sites,
image the diseased sites with MRI, and treat the diseased sites by either releasing a drug in the
presence of an oscillating magnetic field or magnetic hyperthermia. HSA nanoparticles have a
very bright future in biomedicine. One example is the FDA approved Abraxane. Future work
will focus on optimizing the conditions for the release of BODIPY-vinblastine by magnetic
nanoparticles in the presence of an oscillating magnetic field.
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Chapter 6
Discussion

This dissertation has discussed the use of fluorescent quantum dots and protein nanoparticles
in biological applications.

Quantum dots offer several advantages over conventional

fluorophores such as broad absorption spectra, narrow emission spectra, high quantum yield,
high photostability, high chemical stability, and size dependent luminescence. Human serum
albumin protein nanoparticles have the advantages of being inexpensive, nonimmunogenic,
biocompatible, and biodegradeable.

One of the most desirable characteristics of quantum dots is their ability to multiplex.
Several research groups have used quantum dots in multiplexed assays to detect biomolecules
such as multiple DNA targets to specific neurotoxins. Chapter 3 discussed the incorporation of
CdSe/ZnS quantum dots emitting at 545 nm and 655 nm into 35 nm pores of 3 µm mesoporous
silica particles. The quantum dots were stably encapsulated in the pores via strong hydrophobic
interactions between the TOPO molecules on the quantum dot surface and the C-18 hydrocarbon
chain in the mesopore. It was also possible to precisely control the ratio the different emission
wavelength quantum dots in the pores which makes it possible to make several optical codes.
Unlike costly and laborious methods such as spray pyrolysis and microemulsions, the method of
preparing the fluorescent mesoporous silica particles was both rapid and simple.

The

incorporation of the quantum dots into the mesoporous silica spheres was completed in 30
minutes. The quantum dot- silica composites were employed as signal transducers for the
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detection of the breast cancer marker HER2/neu. TEM, SEM, and EDS showed the presence of
quantum dots in the silica pores. Unlike polystyrene microparticles, the rigid silica particles
were resistant to structural deformation. The quantum dot – silica composites showed high
photostability compared to dye labeled mesoporous silica particles and free quantum dots. This
is likely due to the silica shielding the quantum dots from photo-oxidation or photocorrosion.
The composite particles were most stable when stored under argon in the dark. Mesoporous
silica loaded with a 1:1 ratio of 1µM 545 nm and 655 nm quantum dots and labeled with antiHER2 via biotin/avidin interactions successfully detected the HER2/neu. The HER2/neu assay
had a limit of detection of 85 ng/mL with a linear range between 85 ng/mL and 10 µg/mL of
HER2/neu.

The ability to screen for multiple biomarkers is very desirable.

The current gold

standards for detecting breast cancer are fluorescence in situ hybridization (FISH) and
immunohistochemistry (IHC), neither of which can identify multiple biomarkers simultaneously
and are invasive. Chapter 4 discussed in more detail the use of quantum dot – silica composites
for the multiplexed detection of multiple breast cancer markers. Unlike FISH and IHC which
analyze tissue samples, this detection method was minimially invasive in that it analyzed breast
cancer marker concentration in serum samples. Quantum dots emitting at 495 nm, 560, nm, and
655 nm were used to detect HER2/neu, ERa, and PR individually and simultaneously. The
direct detection method which involved the nonspecific adsorption of protein to a glass well plate
was only able to measure abnormal levels of protein. To improve the sensitivity of the assay a
sandwich assay was performed by covalently binding a capture antibody to the glass plate via
EDC/NHS chemistry and using the antibody labeled quantum dot – silica composites as the
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detection. The sandwich assay had approximately a 20 to 30-fold improvement in detection and
was able to detect both normal and abnormal levels of protein. One major disadvantage of
CdSe/ZnS quantm dots is their toxicity. We wanted to demonstrate the capability of nontoxic
InP quantum dots to simultaneously detect the breast cancer markers. The multiplexed detection
with InP quantum dots was successful but had inferior detection limits compared to mesoporous
silica loaded with CdSe/ZnS. These quantum dot encoded particles are novel in that they could
potentially be used in the early detection of HER2/neu, ERa, or PR positive breast cancer. By
using the minimally invasive technique of collecting serum samples, the use of SiQDs as signal
transducers could potentially be used in the early diagnosis of breast cancer and can possibly be
used to either replace or complement FISH and IHC.

A highly attractive alternative to conventional chemotherapy is the controlled release and
targeting of drug agents specifically to diseased sites. Chapter 5 discussed the use of anti-PR
labeled human serum albumin nanoparticles for the in vitro detection of the breast cancer marker
progesterone receptor and the effect of matrix metalloproteinase (MMP) concentration on the
release of drug analogue from the composite particles. Several research groups have used human
serum albumin nanoparticles for the detection and delivery of hydrophobic drug molecules to
diseased cells.

In our study, human serum albumin nanoparticles were loaded with 10 nm

magnetite particles and a fluorescent drug analogue, BODIPY-vinblastine. Cryo-TEM images
revealed speherical, monodispersed particles. The particles were proven to be both fluorescent
and magnetic by mounting the sample vial on a magnet. After 15 minutes, the particles moved
toward the magnet, leaving a clear supernatant. The solution fluoresced under illumination with
a UV lamp.

The release was complete within 24 hours with increasing collagenase
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concentration; whereas, the release was still not complete after 48 hours with increasing MMP11 concentration. The novelty of the antibody – labeled composite particles is their potential use
as a theranostic tool to detect diseased sites, image the diseased sites with MRI, and treat the
diseased sites by either releasing a drug in the presence of an oscillating magnetic field or
magnetic hyperthermia.
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